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Accumulating evidence suggest that the mRNA splicing process is tightly governed 
by complex interactions between numerous trans and cis acting factors. The 
importance of mRNA splicing and the transcript diversity generated through 
alternative mRNA splicing is demonstrated by the high frequency of disease causing 
mutations that alter splicing through disruption of the splice-regulatory factors. 
Despite an increasing number of splicing mutations that influence pharmacogenetic 
responses and hereditary diseases, the effect of genetic polymorphisms on splicing 
remains a largely under-explored area.  
 
This dissertation aims to examine allele-specific splicing in human and mouse using 
publicly available datasets. Such datasets, which have been generated from multiple 
tissue sources and from individuals of diverse backgrounds, are rich and cheap 
reservoirs of transcript isoforms resulting from alternative splicing as well as isoforms 
resulting from mutations or polymorphisms (allele-specific isoforms). Published tools 
were used to analyse microarray and genomic data. However, for the assessment of 
allele-specific splicing using publicly available high-throughput transcript sequences, 
we present two novel methods: a heuristic method for quantifying the prevalence of 
allele-specific splicing and a more sophisticated maximum likelihood method for the 
detection of individual examples of allele-specific splicing. These methods make use 
of transcripts that can be mapped to both polymorphisms and computationally 
predicted mRNA isoforms. Inference of polymorphic alleles from transcripts is 
laborious hence a pre-computed database was created for the human data and made 
publicly available for use by the wider research community. 
  
We propose that 20% and 10% of human and mouse genes, respectively, with 
multiple transcripts are affected by polymorphisms that alter splicing. For the 
detection of individual genes affected by allele-specific splicing we integrated results 
from genome-wide microarray, genomic and transcript-based analyses. Such an 
approach gives more confidence in the predicted candidates. This dissertation is an 
extensive resource which underscores the prevalence and importance of allele-specific 
splicing and will support further investigation of polymorphisms that contribute to 
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The decoding of information stored in a gene to produce protein, via transcription, is 
the central dogma of biology (Crick, 1970). Prior to 1977, eukaryotic genes were 
thought to correspond to continguous stretches of the genome. Based on studies 
performed on the Adenovirus HEXON gene, this understanding of the central dogma 
of biology was drastically transformed by the Nobel winning discovery of the mRNA 
splicing process (Berget, Moore et al. 1977; Chow, Gelinas et al. 1977). Viral and 
eukaryotic genes typically exist in an interrupted manner and undergo mRNA splicing 
which removes the non-coding interrupting sequences and accurately joins together 
the remaining sequences to form mature mRNA sequences. These mature mRNA 
transcripts are then used as templates for the translation of genes into protein. 
 
Alternative splicing: A single gene produces multiple products 
 
Soon after the discovery of mRNA splicing, Walter Gilbert coined the term “intron” 
to refer to the non-coding segments of genes. Of greater significance is his postulate 
that a single pre-mRNA transcript could be used as a fixed template to produce 
multiple distinct mRNA isoforms by varying the demarcations and combinations of 
introns in a process now commonly known as alternative mRNA splicing (Gilbert, 
1978). Experimental evidence supporting Gilbert’s notion soon followed, ending the 
then-widely accepted cistronic nature of genes or the one-gene one peptide 
hypothesis. Little did Gilbert know that he had uncovered a versatile mechanism that 
contributes significantly towards the regulation of gene expression in numerous multi-












Although alternative splicing was discovered in 1978, appreciation of the importance 
of this biochemical process was only achieved during sequencing of the whole human 
genome. Computational analysis led to the discovery that alternative splicing is highly 
prevalent in the human genome (Johnson et al., 2003). From a minor genetic process 
initially estimated to occur in less than 5% of human genes (Sharp, 1994), alternative 
splicing is now considered as a highly prevalent mechanism that occurs in 
approximately 75% of human genes (Johnson et al., 2003)  and  in many other higher 
order organisms (Brett et al., 2002). Structural analyses of the computationally 
predicted alternatively spliced isoforms led to the discovery of the many possible 
modes through which AS can occur (see Figure 1). 
 
 
Figure 1: Although more than 20 different splicing modes exist, only the major classes are illustrated in this 
diagram. This figure was adapted from Graveley, 2001. A) Alternate donor site B) Alternate acceptor site C) Exon 
skipping D) Mutually exclusive exons  E) Intron Retention 
 
Multiple mRNA isoforms can be produced from a single gene, through alternative 
splicing or in an allele-specific manner. Allele-specific splicing is the expression of 
distinct mRNA isoforms or amounts from allelic versions of a gene transcript, which 
contrasts with alternative splicing where distinct mRNA isoforms are processed from 











splicing or allele-specific splicing based on publicly available transcripts alone, 
presents a major challenge. Therefore, computational studies have largely disregarded 
allele-specific splicing and categorized all transcript isoforms as originating from 
alternative splicing (see Chapter 3). 
Allele-specific splicing underlies important phenotypic variations in human including 
disease susceptibility and drug response (Wang and Cooper, 2007). It is critical to 
understand the relevance of alternative splicing in order to fully appreciate the 
pathological effects that allele-specific splicing can have. The importance and specific 
functional roles of alternative splicing provide a platform for making inferences with 
regard to the potential impact of allele-specific splicing.  
 
1.2 Functional impact of alternative splicing 
 
The ability of cells to switch functions in a highly coordinated manner is merely a 
manifestation of alterations occurring at the gene expression level in a timely fashion. 
A complete collection and description of mRNA transcript expression levels and 
proteins in a specific cell at a particular time-point can be described as the 
transcriptome and proteome respectively. Numerous complex regulatory networks 
operate at the transcription and translation levels of gene expression pathways to 
control the transcriptome and proteome. Among gene expression regulatory 
mechanisms, alternative splicing has emerged as a vital component in the regulation 
of the transcriptome in higher eukaryotes (Graveley, 2001; Lopez, 1998). 
 
Detailed molecular studies of many biological processes critical for an organism’s 
viability, such as neural development have shown that alternative splicing is an 
important component of their regulatory systems (Graveley, 2001). However, the 
complete impact of alternative splicing on all biochemical processes is unknown. For 
example, although alternative splicing of the human fibronectin gene was discovered 
more than 20 years ago (Kornblihtt et al., 1984) the precise biological roles of the 20 
main mRNA isoforms are not as yet fully known. Endeavors towards a detailed and 











several decades. Modifications to the transcript caused by alternative splicing can be 




Alternative splicing contributes significantly to proteome diversity. 74% of 
alternatively spliced transcripts are thought to be subjected to changes that affect the 
coding sections of genes (Modrek et al., 2001). The inclusion or exclusion of 
alternative coding segments gives rise to protein isoforms which can perform distinct 
biological functions (Black, 2000; Graveley, 2001). Changes in the peptide sequences 
can modify protein binding affinities, catalytic activities, protein solubility and 
localization (Black, 2000) and in some cases even produce proteins with opposing 
functional roles (Graveley, 2001). 
 
Frequently, alternative splicing events tend to preserve the overall integrity of the 
peptide sequence (Homma et al., 2004; Kriventseva et al., 2003). Proteome diversity 
through alternative splicing can thus be achieved through a gradient of changes that 
occur on a single peptide template, from large changes that include removal of peptide 
segments of more than 100 amino acids in length to subtle amino acid changes. Subtle 
changes are likely to be widespread, for example, single amino acid alterations are 
found in 5% of the human genes with NAGNAG acceptors (Hiller et al., 2004a).  
 
One might expect such subtle protein modifications to have negligible impact on 
protein function, but this has been shown to be untrue (Wen et al., 2004). The 
functional implications of the modifications in the coding region are not necessarily 
controlled by the size of the alternatively spliced region but depend on the functional 




The untranslated regions of mRNAs are rich sites for gene regulatory elements 
(Mossner and Riederer, 2007; Cowles et al., 2002; Rockman and Wray, 2002). 











mRNA regions and can thus affect gene regulatory mechanisms (Modrek et al., 2001). 
Alternative splicing of such sites can control the inclusion or exclusion of important 
cis- regulatory elements thus leading to significant alterations in translation 
efficiency, mRNA stability, mRNA localization and even transcriptional efficiency of 
the gene, thus affecting mRNA expression levels. 
 
1.3 Allele-specific splicing 
 
DNA polymorphisms that exist in splicing regulatory elements can disrupt the mRNA 
splicing pathways and alter splicing patterns in an allele-specific manner. Given the 
enormous impact of alternative mRNA splicing on the regulation of gene expression 
in important biological processes through modifications at the protein and transcript 
levels (Graveley, 2001; Black, 2000a), allele-specific splicing has huge potential to 
disrupt the tightly controlled transcriptomes and proteomes of any cell through similar 
sequence alterations. Such inter-individual changes in the transcriptomes and 
proteomes can result in both subtle and even life-threatening phenotypes (Wang and 
Cooper, 2007). 
 
Numerous examples of allele-specific splicing that contribute to disease progression 
and susceptibility have already been reported in literature (Wang and Cooper, 2007). 
A thorough understanding of the impact of allele-specific splicing on human 
phenotypes opens up immense possibilities of mapping out medically relevant 
phenotypic variations and disease aetiology (Wang and Cooper, 2007). A genome-
wide catalogue and analysis of allele-specific splicing would afford a more holistic 
view and a starting point in unpacking the biological impact of such individual-
specific mRNA splicing events. 
 
1.3.1 Genome-wide detection of allele-specific splicing 
 
Despite the growing appreciation of genome-wide analysis of intra-individual 
variation in alternative splicing, only modest efforts have been made towards the 
study of allele-specific splicing at this level. These, contrasts significantly with the 











an allele-specific manner (see Figure 2 for comparison of allele-specific splicing and 
allele-specific gene expression). In part, this could be due to the fact that transcription 
has been known and studied for a longer period, evident from the establishment of a 
comprehensive database of transcriptional regulatory systems, TRANSFAC, which 
catalogues large volumes of well characterised transcriptional regulatory elements and 
factors (Matys et al., 2006). Databases of similar magnitude for the mRNA splicing 




Figure 2:  Differences between allele-specific gene expression and allele-specific splicing, illustrated using a gene 
transcript with three exons. Allele-specific expression involves quantitative changes that affect the transcription of 
whole gene transcript, while allele-specific splicing is quantitative or qualitative changes that affect only isoforms 
of mRNA transcripts. We have illustrated an allele-specific splicing event that affects the inclusion or exclusion of 
an exon in mRNA isoforms. 
 
Altering pre-existing methods and strategies used on similar systems provides a much 
needed basic frame-work for genome-wide analyses of allele-specific splicing. The 
mRNA splicing and transcriptional gene regulation, are parallel (Table 1), therefore 
hurdles faced in the detection of allele-specific expression are similar to those of 
allele-specific mRNA splicing. Thus many lessons on how to detect genome-wide 
















Attribute Transcription mRNA splicing 
Transcript Global Only segments of mRNA transcripts 
which are alternatively spliced 
Regulatory system Core regulatory elements 
Enhancers, silencers 
Core regulatory elements 
Enhancers and silencers 
Location of cis-acting regulatory 
elements 
Variable positions and 
many are yet to be discovered 
Less variable locations and 
many are yet to be discovered 
Publicly available data Serial Analysis of Gene Expression   
(SAGE) 
 
Expressed sequence tags (ESTs) 
 
Microarrays 




For this current study aimed at genome-wide detection and analyses of allele-specific 
splicing, two major lessons were learnt from previous studies on allele-specific gene 
expression a) basing detection on the principle of linkage disequilibrium, and b) use 
of publicly available transcripts. Arguments for using these two approaches in the 
detection of allele-specific expression are pointed out below.  
 
a) Linkage based analysis 
 
Revealing the extent of cis-acting regulatory mutations on allele-specific expression 
presents a great challenge. Most of the sequence variants that disrupt the regulatory 
networks are hard to predict due to the complex nature of the regulatory networks. 
Genome-wide detection of allele-specific expression could thus be incomplete if 
directed only at mutations which disrupt known transcriptional regulatory elements. 
 
To circumvent this difficulty, one approach that has gained in popularity for the 
detection of allele-specific expression is based on identifying associations between 
gene expression variations and genotypes that are linked to unknown causal variants. 
This procedure greatly increases the power to detect a comprehensive set of allele-
specific expression differences and offers the advantage of simultaneously analyzing 












b) Use of publicly available transcripts 
 
Genome-wide analysis of allele-specific expression requires an extensively sampled 
transcriptome and genotyped sequence polymorphisms. Traditionally, genome-wide 
analyses have been performed on experimental platforms which fulfill both these 
requirements (Cowles et al., 2002; Pastinen et al., 2000). However, these are 
expensive and time-consuming and other cheaper avenues had to be explored to 
facilitate research in this field. 
 
The availability of publicly available transcriptomes that harbor genotype information 
has sparked a paradigm shift in efforts to accelerate the detection and deciphering of 
allele-specific gene expression; from a purely experimental approach to a combination 
of experimental and computational approaches based on publicly available datasets. 
Unintentionally, due to their nature, databases from transcriptome studies have also 
captured allele-specific expression (Ge et al., 2005). Such cheap and rich reservoirs 
have inevitably attracted the interests of many research groups studying allele-specific 
expressing, and produced promising results (Knight, 2004).   
 
1.4 Choice of organisms to study 
 
Allele-specific mRNA splicing can occur in any organism that has multi-exon genes 
and may contribute in the determination of a significant amount of important 
phenotypic variation across individuals. In viruses, allele-specific splicing has been 
implicated in affecting their virulence and pathogenicity (Purcell and Martin, 1993). 
In human allele-specific splicing has been implicated in disease and cancer 
progression (Wang and Cooper, 2007). 
 
The huge potential impact of allele-specific splicing on phenotypic variation 
necessitates its detection in all multi-exon genomes. However, in this thesis we have 
based our study only on the human and mouse genomes. The importance of studying 
mouse is underscored by the observation that it is the preferred and most widely used 
organism for modeling human diseases (Peters et al., 2007). Mouse individuals from a 











specific splicing in mouse is equivalent to strain-specific mRNA splicing, thus this 
term is used throughout this thesis. 
 
This current work is based purely on computational approaches and consequently the 
choice of organism to study is immensely influenced by the availability of data. 
dbEST (Wheeler et al., 2007), the largest public repository of transcriptome data, 
contains transcripts from more than 1500 species.  Human and mouse dominate with 
their transcriptomes making up collectively 25.65% of the data in the dbEST database 
(Figure 3). Therefore, a further reason for studying human and mouse is the extensive 
sampling of the mouse and human transcriptomes in the dbEST database. 
 
 
Figure 3:  Biased transcript representation towards the human and mouse genomes in the dbEST database version 
031408. A total of 50622371 transcripts from 1516 organisms are represented in dbEST and in the pie-chart above. 
For clarity, only data from human and mouse are labelled. 
 
1.5. Thesis organization 
 
A major goal in the field of genetics is to define, globally, the relationship between 
genotype, gene expression and phenotypic variations. Towards this end, efforts have 











specific global gene expression patterns (Knight, 2004; Knight, 2006). This thesis 
instead aims to emphasize allele-specific splicing, which has been largely disregarded. 
Publicly available transcript datasets are exploited to perform a comprehensive 
genome-wide survey and characterization of allele-specific splicing in human and 
mouse.  
 
A general literature review is presented in Chapter 2. This chapter highlights the 
important role and usefulness of ESTs in the detection of splicing. The high 
prevalence of alternative splicing has motivated a large body of work aimed at 
understanding the regulation of alternative splicing. This knowledge of splicing 
regulatory elements has been instrumental in the detection and understanding of the 
impact of mutations that disrupt splicing. In conclusion, tools and methods that can be 
used for the detection and characterization of splicing mutations are also reviewed. 
 
Chapters 3-6 are based on specific research questions that involved extensive data 
analyses. Each chapter is thus presented as a separate entity.  
 
The recent recognition that studies on allele-specific expression and allele-specific 
splicing could be facilitated by use of publicly available data prompted the 
development of a pre-computed database of polymorphisms that map to expressed 
sequence tags (ESTs). This database is presented in Chapter 3.  
 
Before an in-depth analysis of allele-specific splicing could be performed, we 
quantified the extent to which the observed transcript variants in a publicly available 
database of presumed alternatively spliced mRNA isoforms is influenced by allele-
specific mRNA splicing. For this analysis, a novel heuristic method was developed 
based on the principle of linkage disequilibrium between unknown cis-acting 
mutations and observable and genotyped mutations. The approach applied to human 
data in Chapter 4 was also used for the estimation of the prevalence of mouse strain-
specific splicing in Chapter 6.  
 
Chapter 5 presents an integrated analysis by three publicly available datasets 
(microarray, expressed sequence tags and genomic sequences), for the detection of 











and genomic data. A maximum likelihood approach was implemented that makes 
better use of the EST data for detecting allele-specific splicing than the heuristic 
method presented in Chapter 4. Putative cis-acting mutations that alter splicing by 
disrupting well established cis-acting regulatory elements were detected by applying 
ab inito prediction tools to genomic sequence data. 
  
Chapter 7 is a concluding chapter and it highlights the main findings and gives a 











































Considerable effort has been made towards understanding networks that contribute to 
the regulation of mRNA splicing and alternative splicing of pre-mRNA transcripts. 
Much of the progress made towards understanding mRNA splicing is attributed to 
Expressed Sequence Tag (EST) and microarray technologies which permit large-scale 
detection and subsequent cataloguing of alternatively spliced pre-mRNA isoforms. 
This review provides a general overview of alternative splicing, its detection and 
cataloguing into databases. Although these databases of alternatively spliced pre-
mRNA transcripts are useful resources, the impact of noise from other mechanisms 
such as allele-specific splicing is largely unknown and these are discussed in this 
review. Pointers to the multiple splicing regulatory elements and other gene 
expression mechanisms which if disrupted by mutations can result in allele-specific 
splicing are also highlighted. The huge impact of splicing mutations on human 
diseases and pharmacogenetics has made the characterisation and the detection of 























2.1 pre-mRNA splicing and alternative splicing 
2.1.1 Pre-mRNA splicing  
 
A significant number of eukaryotic and virus genes are interrupted by introns (see 
Chapter 1). Therefore, accurate removal of the introns through pre-mRNA splicing, 
plays a major role in the expression of genes in higher order organisms. The 
importance of the pre-mRNA splicing is underscored by the high prevalence of 
disease-causing mutations that affect the splicing process (Krawczak et al., 1992; 
Lopez-Bigas et al., 2005).  
 
The mRNA splicing reaction occurs in well defined, highly catalytic trans-
esterification reactions (Figure 1). This process occurs within a dynamic structure 
known as the spliceosome which is made up of five U-rich small ribonucleoproteins 
(snRNPs), namely U1, U2, U4, U5 and U6, and more than 50 proteins (Lopez, 1998). 
The spliceosome is largely controlled by complex interactions between spliceosome 
factors and core splicing cis-acting elements encoded within the mRNA transcript, 
which include the donor, acceptor, polypyrimidine tract and the branch point as 
shown in Figure 1. The splicing process results in the release of introns via formation 
of lariat structures and is concluded by accurate annealing of the 5’ exon and 3’ exon 
of the spliced out introns (Figure 1a). 
 
2.1.1.1 Splice site recognition 
 
Before catalyzing the splicing process, the spliceosome has to identify the introns or 
splice sites. The spliceosome defines splice sites based on the terminal di-nucleotide 
bases of the introns, which are usually GT and AG for donor and acceptor sites, 
respectively (Lopez, 1998). Although these are the only four bases in the splice sites 
that are highly conserved, additional nucleotides that flank these di-nucleotides make 
up the consensus sequence are required for the U1 snRNP to bind to the donor site 
and the SF1/U2snRNP to bind to the acceptor site (Figure 1). About 9 bases define the 
donor site and approximately 23 bases define the acceptor sites (Yeo and Burge, 











of the U1 factor to the donor site, and that of the U2AF trans-acting factor to the 
acceptor site (Lopez, 1998; Smith and Valcarcel, 2000). 
 
A major obstacle faced by the spliceosome in accurately demarcating splice sites is 
the abundance of cryptic splice sites in the genomes that can attract the spliceosome 
with equal or even better efficiency than authentic splice sites (Baralle and Baralle, 
2005). For example, in the human HPRT gene, the spliceosome has to identify 9 
authentic exons from over 100 potential donor sites and over 600 potential acceptor 
sites (Sun and Chasin, 2000). The information within the core splicing signals (donor, 
acceptor and polypyrimidine tract) is insufficient for the spliceosome to precisely 
distinguish weak authentic splice sites amidst such large numbers of potential splice 




Figure 1:  Cis-regulatory elements involved in the detection of splice sites and the splicing out process 1: Branch 
point, 2 and 3: Acceptor sites these include the polypyrimidine tract, 4: Exon Splicing Enhancers (ESE), 5: Exon 
Splicing Silencers (ESS), 6: Donor site, 7 and 8:  Intronic Splicing Enhancers (ISE) and 9: Intron Splicing 












Two types of auxiliary elements exist, enhancers and silencers which are found both 
in exons and introns and are named accordingly; Exon Splicing Enhancers (ESEs), 
Exon Splicing Silencer Elements (ESSs), Intron Splicing Enhancers (ISEs) and Intron 
Splicing Silencers (ISSs) (Lopez, 1998). As the names suggest, enhancer elements 
promote the recognition of authentic splice sites by the spliceosome while silencers 
encourage the spliceosome to by-pass cryptic splice sites.  
Enhancer elements 
 
Enhancer elements facilitate recruitment of spliceosome factors to splice sites. Trans-
acting factors that can bind to the enhancer elements through their RNA-binding 
domains recruit components of the spliceosome to splice-sites through protein-protein 
interactions (Lopez, 1998). Strong ESEs are commonly found near exons that are 
bordered by introns with weak splice signals (Dewey et al., 2006). Therefore, a 
compensatory relationship exists between ESEs and splice sites. 
 
Extensive computational studies have revealed the existence of many different classes 
of enhancer elements in constitutively spliced exons (Zhang et al., 2005; Cartegni et 
al., 2002). For example, G-rich elements have previously been identified that support 
the recognition of small constitutively spliced exons (McCullough and Berget, 1997).  
Different splicing enhancer elements are characterised by different nucleotide 
compositions with different substrate specificities (Ladd and Cooper, 2002). These 
different characteristics are likely to be the foundation of inconsistencies in the 
distance between ESEs and splice sites. Although there is a general enrichment of 
ESEs within 125 base pairs of splice junctions (Fairbrother et al., 2004; Majewski and 
Ott, 2002), some strong ESEs can still exert that function more than 1000 bases away 
from the splice junctions (Hull et al., 2007). 
 
Of all the enhancer elements, the best studied are exonic enhancer elements from the 
serine-arginine (SR) family of splicing factors. The most significant work on SR-
specific ESEs is from the Krainer Laboratory (Liu et al., 2000; Liu et al., 1998). 
Instead of using computational methods to detect ESEs, they used an experimental 
approach that functionally selects for ESE motifs (6-8 nucleotides in length) enriched 











Evolution of Ligands by Exponential enrichment), which is commonly used to 
identify functional ligands. To facilitate the use of ESEs identified using the SELEX 
method, Cartegni and co-workers (Cartegni and Krainer, 2003), used their ESE motifs 
to develop scoring matrices and implemented these in the ESEfinder web-based 
program. Users can then predict putative SR-specific ESEs by scanning and scoring 




Silencer sequences when bound by trans-acting factors hinder the binding of the 
spliceosome to the mRNA transcript. Of all the silencer elements, the best known are 
those bound by the hnRNP factors (Cartegni et al., 2002). Interestingly, the 
polypyrimidine tract can also act as a silencer element when bound to the hnRNP 
splicing factor in addition to other splicing factors that hinder the interaction of the 
U2AF spliceosome factor to the acceptor site (Cartegni et al., 2002). An example is 
that of the SXL (Sex Lethal) protein in Drosophila which binds to the polypyrimidine 
tract of a specific acceptor site and reroutes the U2AF factor to another site (Lopez, 
1998). 
2.1.1.2 Splice site recognition mechanisms  
 
One pivotal question in the mRNA splicing process is the exact process by which the 
splicing machinery is assisted by auxiliary regulatory elements to recognize splice 
sites. In vitro splicing assays have shown that the exon/intron architecture of genes 
determines how the spliceosome recognizes splices sites (Berget, 1995; Sterner et al., 
1996; Robberson et al., 1990; Talerico and Berget, 1994). Depending on intron and 
exon size, splice site recognition by the spliceosome can occur via the intron or exon. 
The length is important because for the splicing process to occur, interactions between 















Figure 2: Splice site recognition mechanisms. A) Exon recognition is facilitated across exons. The enhancer 
molecules bind to their cis-acting elements and recruit the spliceosome factors B) Intron recognition is facilitated 
via the introns when introns are short enough to allow interactions between the U1 and U2 splicing factors which 
promote the progression of the splicing process C) Recursive splicing; Long introns can have splice sites 
embedded within them which can be used by the spliceosome. These sites are then used to  splice out sections of 
the introns in a recursive manner  D) Intra-splicing; In this model, “intraintrons” (colored blue and orange)  and 
“intraexons” (dotted boxes) can exist within long introns ” (Ott et al., 2003).  The spliceosome recognizes and 
splices out the intraintrons and hence shortening the overall intron length. When the introns length is short enough 
and composed only of intraexons, it is then spliced out via one of the less complex mechanisms such as the exon 













The average length of introns is much longer than that of exons in the human genome 
(Venter et al., 2001). Therefore, the recognition of splice sites in human occurs via the 
exon recognition mechanism since most human exons are short enough to allow for 
interactions between the 3’ and 5’ splice junctions via SR proteins (Berget, 1995; 
Robberson et al., 1990) (Figure 2). Consistent with this mechanism lengthening of 
small exons that are flanked by long introns results in exon skipping (Sterner et al., 
1996). The optimal exon length for the exon recognition splice site mechanism has 
been reported to be 50-300 bps (Berget, 1995). This optimal length was established 




In other lower organisms such as Drosophila and in plants, the introns are on average 
much shorter than the exons, and this observation supports splice site recognition via 
intron recognition (Talerico and Berget, 1994) (Figure 2). An upper limit of intron 
length of 200-250 bps has been suggested for the intron-recognition model (Fox-
Walsh et al., 2005). The most prevalent form of regulated splicing in plants and lower 




For short exons embedded within long introns, the most likely splice site recognition 
mechanism would be via the exon definition mechanism (Berget, 1995). However, the 
splicing out of very long introns would take a long time. For  genes such as the 
dystrophin gene which has very long introns (over 10kb), the mRNA splicing process 
via exon recognition takes 36 hrs in comparison to genes with small introns which 
take minutes (Tennyson et al., 1996). Such slow excision of the introns would also 
encourage the formation of secondary structures through complementary base pairing. 
A recently proposed and intriguing mechanism is that of recursive splicing (Hatton et 
al., 1998; Burnette et al., 2005).  In this model, very long introns (longer than 10kb) 











steps (Burnette et al., 2005; Hatton et al., 1998).  Burnette et al., (2005), identified 
124 introns in Drosophila that are spliced out via the recursive splicing mechanism 
and performed experimental validations for some of these introns through in vitro 
experiments. Because Drosophila has a much lower percentage of introns above 
10kbs than humans, recursive splicing could be a common process used to splice out 
approximately 10% of long introns found in the human genome (Deutsch et al., 2008). 
Intra-splicing  
 
An alternative model has been proposed to explain how very long introns are spliced 
out, namely the “intrasplicing” model (Ott et al., 2003). This model proposes that the 
splicing machinery first processes the long introns while ignoring the donor sites, and 
then uses the donor site right at the end (Figure 2). However, this model is based on 
computational predictions and is yet to be confirmed experimentally (Ott et al., 2003). 
 
2.1.2 Alternative splicing: Mechanism and Regulation 
The pre-mRNA splicing process is a much more complicated process as a single pre-
mRNA can be alternatively spliced to give multiple distinct mature transcripts 
(Graveley, 2001). Such AS is often highly regulated and is thus critical for proper 
functioning of major human physiological and cellular processes as it greatly expands 
the protein diversity and contributes to the overall complexity of gene expression 
(Smith and Valcarcel, 2000). Based on large-scale AS detection technologies such as 
ESTs and microarrays, over 70% of human genes are estimated to be alternatively 
spliced (Johnson et al., 2003). The detection of such a high frequency of AS in human 
as well as other eukaryotic organisms sparked a renewed interest in the field of 
mRNA splicing and alternative splicing (Brett et al., 2002).  
 
Significant efforts are currently underway to unravel the complex systems involved in 
mRNA splicing and AS (Cartegni et al., 2003). The shift from simple mRNA splicing 
to alternative splicing is largely enabled by complex regulatory systems that control 
the ability of the spliceosome to switch between different alternative splicing 











single mRNA transcript (Graveley, 2001). The discovery of a 115 exon gene in 
Drosophila melanogaster  which encodes the axonal guidance cell receptor molecule 
and has the potential to generate over 38 000 mRNA transcripts through alternative 
splicing of its pre-mRNA transcript, provides one example, albeit extreme of the 
potential contribution of alternative splicing to transcript diversity (Schmucker et al., 
2000). 
 
Alternative inclusion/exclusion of exons/introns is influenced by splice-site strength, 
pre-mRNA secondary structure (Coleman and Roesser, 1998), splice site recognition 
mechanisms, and complex interactions between cis and trans-acting factors. 
Alternatively spliced exons are enriched with enhancer and silencer molecules to aid 
in their regulation (Smith and Valcarcel, 2000). Differential interactions of trans-
acting factors with enhancer and silencer elements control the spliceosome’s ability to 
switch between different alternative splicing pathways. In comparison to 
constitutively spliced exons, alternatively spliced exons (Baek and Green, 2005; Itoh 
et al., 2004) are weak and are flanked by highly conserved intron sequences, 
suggestive of an enrichment of auxiliary regulatory elements (Sorek and Ast, 2003). 
 
2.1.2.1 Cis-regulatory elements 
 
Considerable investigation has gone into deciphering the regulatory elements that 
govern alternative splicing; however, the list is far from being exhaustive (Ladd and 
Cooper, 2002). Our poor knowledge of the splicing process is highlighted by the 
continual discovery of splice regulatory elements (Yeo et al., 2007). Identifying cis-
elements that regulate AS in so many context-specific splicing events is a major task. 
A difficulty in the detection of enhancer and silencer elements that form part of the 
alternative splicing regulatory network is that alternative splicing can be regulated by 
the core cis-elements and also by other cis-acting elements which are not part of the 
basal splicing regulatory system.  
 
Unknown cis-acting elements have been highlighted by different methods which 
include natural and directed mutagenesis at random locations in the mRNA transcripts 
and assessing whether they cause aberrant splicing events (Pagani et al., 2005; Raponi 











on the cystic fibrosis gene and more than 50% of the point mutations were observed 
to cause splicing defects (Pagani et al., 2005). 
 
Computational and comparative genomics approaches have also led to the detection 
of several alternative splicing-specific enhancer and silencer elements. However, the 
variable location of enhancer and silencer sequences relative to the splice junction 
complicates the computational detection of enhancers and silencers (see section 
2.1.1). Furthermore, cis elements are usually characterised by unique consensus 
sequences. For example, brain-specific alternative exons are flanked by a splicing 
regulatory element UGCAUG (Minovitsky et al., 2005). Although this element was 
detected computationally, its conservation in brain-specific exons in mouse suggests 
that it is an important functional regulator of brain-specific alternative splicing events. 
 
Variations in the manipulation of activities or amounts of trans-acting factors during 
development or in different tissues can lead to the enhancer and silencer elements 
involved in splice site recognition contributing to the regulation of AS. For example, 
high concentrations of SR proteins in comparison to hnRNP proteins favors the use of 
proximal sites and exon inclusion (Ladd and Cooper, 2002), while a higher abundance 
of hnRNP factors promotes the use of distal splice sites and exon skipping (Ladd and 
Cooper, 2002).  
 
Splicing factors such as SR proteins have the ability to auto-regulate their own 
transcript levels (Lareau et al., 2007). Auto regulation of trans-acting factors has been 
shown to occur through coupling of the unproductive splicing with degradation 
(Lareau et al., 2007).  However, a commonly reported means of regulating the SR 
protein concentration is at the activation stage. SR protein factors require activation 
through phosphorylation in order to facilitate the splicing trans-esterification 
reactions (Faustino and Cooper, 2003). Numerous extra-cellular stimuli such as 
hormones, immune response, neuronal activities or external factors such as food can 
control the relative abundance of enhancer and silencer splicing factors in a cell-
specific or developmental specific manner (Faustino and Cooper, 2003).  
 
Such extra-cellular stimuli that trigger a cascade of reactions which lead to a kinase 











inclusion or exclusion of an exon or intron (Faustino and Cooper, 2003). The 
activation of an SRp40 enhancer protein by insulin for the exon inclusion of a protein 
kinase C (PKC) isoform is an ideal case for illustrating a hormone regulated 
alternative splicing event (Chalfant et al., 1995). Phosphorylation of the SRp40 
enhancer protein that promotes inclusion of an exon of the PKC mRNA is catalyzed 
by an unknown kinase enzyme. This phosphorylation reaction is activated by a 
cascade of reactions which are triggered when an insulin receptor is activated by 
insulin.   
 
Manipulation of trans-acting factors may give rise to novel therapeutic approaches for 
correcting aberrant splicing (Faustino and Cooper, 2003). A noteworthy achievement 
of the post-genomic era would be a database that documents all trans-acting factors, 
the motifs they bind to and the genes they affect. Such an undertaking is however, not 
a trivial task as some of the splicing factors themselves are subject to alternative 
splicing and their splicing is governed by other trans-acting factors (Nakahata and 
Kawamoto, 2005; Wu et al., 2002). An added complexity in the detection and 
cataloguing of trans-acting factors is that some trans-acting factors can act both as 
enhancers and silencers.  
 
2.1.2.2 Coupling of alternative splicing regulation to other 
regulatory systems 
 
AS occurs concurrently with other gene expression regulatory mechanisms that 
control transcription (Chern et al., 2008), nonsense mediate decay (NMD) (Green et 
al., 2003; Lewis et al., 2003), and imprinting. Although these mechanisms are clearly 
distinct from AS, with some exceptions (Bhasi et al., 2007), it is surprising that 
researchers still do not make a clear distinction between alternative polyadenylation 
and transcription start sites from alternative mRNA splicing (see section 2.3.1). 
Adding to this confusion, alternative splicing regulation of some mRNA isoforms 
seems interconnected to these gene expression regulatory systems (Kornblihtt, 2007; 
Zavolan et al., 2003).  
 
Using full-length cDNAs, Zavolan and coworkers (2003), showed that alternative use 











2008). The position at which RNA pol II initiates transcription or positions at which 
the RNA pol II stalls could lead to different splice patterns (Kornblihtt, 2007; 
Kornblihtt, 2005). Therefore, variations in activity or binding sites of the RNA pol II 
during transcription can induce mRNA splicing variations.  
 
Premature termination codons (PTCs) which elicit the NMD system can be introduced 
by AS events (Lewis et al., 2003; Green et al., 2003). This coupling of the NMD and 
splicing results in the down-regulation of gene expression and such coupling has been 
reported for many genes including drug transporters such as the ABCC4 gene (Lamba 
et al., 2003). Interestingly, the two exons that are inserted through AS, introducing a 
PTC in the ABCC4 gene are highly conserved across human, mouse and monkey. 
This suggests that the regulation of this gene via NMD is evolutionarily conserved 
and therefore, functionally important. The coupling of the NMD and splicing in 
regulating gene expression is now commonly referred to as RUST (regulated 
unproductive splicing and translation) as coined by Lewis et al., (2003). 
 
 Based on EST and cDNA analysis, Lewis and coworkers (2003) reported that at least 
35% of alternatively spliced transcripts contain PTCs. This discovery led to 
assumption that RUST may be a widespread mechanism in the human genome for 
regulating tissue-specific gene expression. However, this speculation was recently 
interrogated. Using a quantitative microarray platform, Pan and coworkers (2006) 
compared levels of splice variants with PTC versus non-PTC containing splice variant 
in 10 different adult mouse tissues. Their results showed that the steady state levels of 
a majority of PTC-containing splice variants rarely varied according to tissue-type, 
which implies that RUST might not be as widespread as previously estimated by 
Lewis et al., (2003).  
 
Imprinting of splice variants in an isoform-specific manner can occur, thus regulating 
expression of specific mRNA isoforms. For example, out of the five known GRB10 
isoforms, one is expressed in skeletal muscle from the maternal allele only, while all 
five GRB10 mRNA splice variants are expressed from both parental alleles in 
numerous other fetal tissues (Blagitko et al., 2000). The reason why this coupling 
occurs is not yet clear and thus further complicating our understanding of the 












2.2 Large-scale detection of alternative splicing 
2.2.1 ESTs  
 
As a result of whole genome sequencing efforts, the human genome sequence and 
genome-wide Expressed Sequence Tags (ESTs) were made publicly available (Venter 
et al., 2001). The genome sequence captures the 3 billion DNA bases that make up the 
human genome while ESTs target 10% of the expressed section of the genome that 
contain gene units. Their primary use was intended for gene discovery and annotation, 
however, the realisation that ESTs are instrumental for the detection of alternative 
splicing patterns (Wolfsberg and Landsman, 1997), captured the attention of the 
genomics research community.  
 
ESTs are single pass unedited sequences that are targeted at capturing the 
transcriptomes from specific tissues at a particular stage (Rezvani et al., 2000; 
Bonaldo et al., 1996; Rezvani and Liew, 2000; Wolfsberg and Landsman, 1997). Due 
to their nature and the manner in which they are generated, ESTs form the basis of 
numerous AS detection protocols. ESTs are also continually mined to further 
characterise alternative splicing events and have thus become invaluable in 
understanding the AS process (Lee and Wang, 2005).  
 
2.2.1.1 Generation and storage of ESTs 
 
The initial stage in the production of ESTs involves harvesting of mRNA from the 
tissue of interest. mRNA transcripts are generated in the nucleus within which they 
are free from degradation by RNAase cytoplasm-bound enzymes. However, outside 
of the nucleus, mRNAs are highly unstable molecules characterised by short half-
lives. It is therefore unfeasible, if not impossible to produce ESTs directly from the 
mRNA species. After extraction of the mRNA transcripts from tissue samples, the 
mRNA transcripts are converted into complementary cDNA from which ESTs are 















Figure 3: A general overview of the production of ESTs. The bias, contaminants and errors that can occur at each 
stage are highlighted. 
 
 
The EST generation protocol allows for rapid generation of large quantities of 
transcripts. Hence there was a need to develop a number of databases aimed at 
housing and making ESTs accessible to the public via the internet. One of the largest 
databases is dbEST and the current version includes data from more than 1500 species 
with more than 50 million ESTs (see Chapter 1). Alternative splicing and many other 














2.2.1.2 EST based detection of alternative splicing 
 
Excluding house-keeping mRNA transcripts, genes express specific mRNA isoforms 
in different tissues or cell-types according to their physiological or biochemical 
requirements. The different research centres which sequence ESTs, extract mRNA 
sequences from a wide range of tissue-types and from different expression states which 
makes ESTs a rich resource for tissue-specific (Xu et al., 2002), disease-specific 
(Aouacheria et al., 2006), and developmental specific mRNA isoforms. What makes EST 
sequences even more valuable for research is that the tissue of origin, developmental 
stage and disease states are included in the annotations of ESTs. Ontologies such as 
eVOC have even been developed to make full use of such information provided by 
the sequencing centres (Kelso et al., 2003). 
 
Identification of alternatively spliced mRNA isoforms 
 
Prior to the whole genome sequencing efforts, alternative splicing studies were few 
because the commonly used RT-PCR method, could not paint a global picture of the 
prevalence of alternative splicing. Currently, there are several other large-scale non-
EST based datasets for the detection of alternative splicing such as protein domains 
(Hiller et al., 2004b) and  processed pseudogenes (Shemesh et al., 2006). However, 
ESTs have remained the major contributors and focal points in large-scale detection 
and verification of alternative splicing events. 
 
Numerous algorithms have since been developed for the detection of alternative 
splicing using ESTs however the underlying strategy is based on aligning ESTs to a 
genomic/mRNA/intronic template sequence which allows introns to be identified as 
gaps and exons as the aligned parts (Modrek and Lee, 2002). Differences in insertions 
and deletions of at least two overlapping ESTs from the same gene could be 
interpreted as evidence of alternative splicing (Figure 4).  
 
False negative and positives can occur as a result of bias, contaminants and 
sequencing errors as described in Figure 3, and thus verification of AS detected using 
ESTs is required. The main advantage is that ESTs provide the structural changes that 











microarrays and RT-PCR methods (Figure 4) that are commonly used for verification 
require a priori knowledge of the gene structure and can thus be performed much 
more readily. Exons and alternatively spliced splice sites detected via ESTs now 
frequently form the basis of large-scale microarray based AS detection and analysis 
(Johnson et al., 2003; Pan et al., 2006). 
 
Verification of putative mRNA isoforms based on ESTs has largely thus far shown a 
high degree of accuracy in the EST based methods (Modrek et al., 2001; Brett et al., 
2000). For example, out of 20 EST based putative mRNA isoforms, 16 were verified 
using the RT-PCR based approach (Brett et al., 2000). Furthermore, several 
alternatively spliced isoforms detected using EST data analysis had previously been 
reported by other independent researchers (Mironov et al., 1999; Brett et al., 2000).   
 
ESTs are, on average, 300-500bps in length and are thus limited in the 
characterization of full length of alternatively spliced isoforms as they capture mainly 
partial gene segments (Nagaraj et al., 2007). Full-length cDNAs are more suited for 
the characterization of all splice variations occurring in a gene. Although the number 
of full-length cDNAs is increasing, they are still much fewer than ESTs (Modrek and 
Lee, 2002). Given the recent increase in sophisticated methods such as splicing graphs 
that are able to stitch together and permit visualisation of the full-length transcript 
isoforms from EST fragments (Malde et al., 2005; Eyras et al., 2004; Xing et al., 
2004),  ESTs are likely to remain an important source of data for the detection of 














Figure 4: A hypothetical exon skipping event. A) Detection of AS using ESTs. EST 5 supports an exon inclusion 
which is alternatively skipped in all the other transcripts. B) RT-PCR primers are designed that are amplified to 
include the alternatively spliced exon. Use of a restriction enzyme to digest the mRNA isoforms followed by gel 
electrophoresis will clearly illustrate the differences in size of the mRNA transcripts.  Adapted from (Modrek and 
Lee, 2002), and (Wang and Cooper, 2007). C)  Exon arrays. Exon-probes are designed to target exon or/and exon 
junctions. Statistical tools are then used to determine the alternative splicing events based on the hybridisation of 
these probes from a single gene on spotted arrays or commercial arrays. 
 
While mRNAs (Brett et al., 2000; Venter et al., 2001) and introns  can be used as 
templates to which EST are aligned for the detection of AS, genomic sequences are 
the currently preferred templates (Kan et al., 2004; Kim et al., 2007; Modrek et al., 
2001) (Figure 4). The use of genomic sequences as templates has several advantages. 











controlling false positives that could be introduced by paralogous sequences, sequence 
errors and contaminants. Furthermore, the exon/intron structures of isoforms can be 
confirmed and the AG-GT canonical donor and acceptor sites in genomic sequences 
that mark the bulk of functional intron termini can be used to substantiate intronic 
structures (Modrek et al., 2001).  
 
2.2.1.3 Cross-species comparison 
 
The identification of genome-wide AS in an organism using ESTs relies on the 
completeness of the ESTs in capturing all the transcriptomes (Modrek and Lee, 2002). 
However, ESTs under-sample the transcriptomes, even in the most highly represented 
organism such as human, resulting in the under-representation of EST-detected AS 
events. This has motivated an extension in the use of ESTs to include cross-species 
based detection of alternative splicing because the splice-sites are conserved across 
different genomes and in closely related genomes (Kan et al., 2004). Furthermore, 
transcriptomes sampled using ESTs from different organisms are never identical nor 
are they of the same magnitude (Brett et al., 2002). Therefore, aligning ESTs from 
one organism to genomes of closely related organisms can be used to detect novel 
isoforms missed during the commonly used transcript to genome comparison, within 
the same organism. 
 
Human and mouse diverged approximately 100 million years ago (Kumar and 
Hedges, 1998) and therefore still share considerable high percentages of sequence 
similarity ranging between 70-88%  at the nucleotide levels, between pairs of 
orthologs, in most functionally important genes (Makalowski et al., 1996; 
Makalowski and Boguski, 1998). Kan et al., (2004) exploited the conservation that 
exists between orthologous mouse and human genes by performing cross-species 
transcript to genome comparisons to detect AS. ESTs from human were aligned to the 
mouse genomic sequences for over 7000 orthologous gene pairs. The same approach 
was performed for the detection of AS in human. The main limitation of this method 
is that some orthologs are likely to have diverged to such an extent that ESTs from 
one organism cannot be aligned accurately to the genomic sequences of another. 
However, the study managed to positively identify previously published alternatively 











through transcript to genome comparisons of the same genome. This cross-species 
comparison approach promises to provide valuable insights of AS in species that are 




Microarrays are platforms that permit characterisation of the transcriptome based on 
hybridisation between immobilised nucleic acids and nucleic acids from a tissue 
source under investigation. These were primarily designed for capturing gene 
expression levels and the immobilized DNA probes were designed to be 
complementary to the 3’ untranslated regions (Srinivasan et al., 2005). After 
numerous exploratory studies it became clear that microarrays can be used to detect 
alternative splicing (Castle et al., 2003; Shoemaker et al., 2001; Srinivasan et al., 
2005; Clark et al., 2002). When probes are designed for exons in a transcript (Figure 
4), alternative splicing could result in either a loss or gain of hybridisation for specific 
probes targeting the affected regions relative to the other probes in the gene (Wang 
and Cooper, 2007). For example, the exon skipping event illustrated in Figure 4 
would result in loss of signal from the probe set targeting the affected exon as well as 
the exon junction probes.  
 
There are two ways in which probes can be designed, either by creating tilling arrays 
or creating probes for known exons/exon junctions (Pan et al., 2004; Johnson et al., 
2003). While both methods require a priori knowledge of the gene structure, the exon 
junction method requires further knowledge of the splicing patterns of exons (Lee and 
Roy, 2004). Hence, the AS events detected using ESTs have frequently formed the 
basis of large-scale microarrays aimed at analysing alternative splicing (Lee and Roy, 
2004; Modrek and Lee, 2002). These include tissue-specific splicing, and even 
quantification of alternatively spliced isoforms (Johnson et al., 2003; Pan et al., 2004; 
Pan et al., 2004). 
 
Exon junctions greatly improve the coverage and reliability of microarrays in 
detecting subtle alternative splicing events and therefore, microarrays are increasingly 











and Roy, 2004; Lee and Wang, 2005; Wang and Cooper, 2007). However, in 
comparison to ESTs, microarrays are restricted in their coverage of transcriptomes 
(Johnson et al., 2003). Although microarrays have some well defined advantages, 
these platforms are unlikely to replace ESTs but rather compliment these versatile 
transcripts. 
 
2.3 Databases of alternatively spliced mRNA isoforms 
 
Large-scale detection of AS has led to the creation of numerous databases to facilitate 
research in this area (Table 1). The different methodologies and datasets used result in 
considerable differences in the databases dedicated to AS and these include the 
organisms analyzed, the number of mRNA isoforms, database structure and 
annotations (Bonizzoni et al., 2006). A unifying characteristic of most AS databases is 
that they are constructed from computational comparisons of ESTs to genomic DNA 
of known genes (Holste and Ohler, 2008). Thus, most of these AS databases retain the 
nomenclatures and annotations used in publicly available genome databases such as 
ENSEMBL (Birney et al., 2006), UNIGENE and SWISS-PROT (Boeckmann et al., 
2003).  
 
Most databases of computationally predicted mRNA isoforms have extra database-
specific features in addition to the mRNA isoforms such as splicing conservation, 
putative splicing regulatory elements, predicted coding sequences and even include 
evidence from published literature to authenticate their computationally predicted AS 
splicing events  (Table 1). These extra features aid in reducing the impact of 
nonfunctional AS errors associated with the technologies used in the detection of AS 
and the shortcomings of the algorithms used. This integration of AS databases to other 
resources which gives them extra features, makes it easier and less timing consuming 












Table 1:  Databases of alternatively spliced mRNA isoforms 
Database Data type Organisms Extra Features Other genome databases 
integrated with AS databases 
References 
ASAPII ESTs and mRNAs 
 
Human plus 13 other 
eukaryotic organisms 
 















-Annotation of putative ESEs and ESS 
 









Manually curated from published 
literature 





(Zheng et al., 
2005) 
 
SpliceInfo Based on PROSPLICER  Human -Secondary structure prediction tool 
-Other regulatory elements discovery 
tools 
Ensembl  




(Huang et al., 
2005) 
PASLDB EST, protein and mRNA alignment 




-- GO terms (Huang et al., 
2002) 
PROSPLICER EST, Protein and mRNA aligned to 
genomic sequence 
Human -- Ensembl     Hugo   SwissProt 
Protein 
UniGene 




Transcript annotations in GenBank 
 
23 Organisms Hypelinked to OMIM 
Etc 
SwissProt:  
  EMBL :  
  UniGene Hugo   Ensembl RefSEq 
OMIM  
 












2.3.1 Impact of EST limitations on databases of alternative splicing 
 
Microarray and EST technologies are each associated with their own limitations and 
these can influence the quality and reliability of mRNA isoforms in databases of AS. 
Currently, most AS databases are based on ESTs (Lee and Wang, 2005) and hence 
limitations of ESTs on AS databases will be discussed. Several contaminants, sequencing 
errors and biases innate in the EST generation protocols contribute to EST quality 
degradation (Figure 3). Such impurities and biases associated with ESTs can cause 
spurious detection of AS and this can have a significant impact on the interpretation of 
results from the databases of alternatively spliced genes. Therefore, it is essential to 
eliminate any contaminants and artefacts as well as take into account most of the biases. 
However, there is currently no way to guarantee that all the problematic sequences are 
filtered out. False positives and negatives can arise in the publicly available transcripts 




ESTs under-represent alternatively spliced isoforms due to the bias that exists in the EST 
generation protocol and also due to the nature of the mRNA transcripts. The biases in the 
EST data are reflected in studies which illustrate that only a fraction of genes are 
represented in the EST data. For example, only about half of the annotated genes on 
human chromosome 22 are represented by ESTs (de Souza et al., 2000).  The likelihood 
of detecting AS using EST data seems to be positively correlated with the gene 
expression levels and the isoform expression levels. Genes with more than 300 ESTs are 
characterized by much higher numbers of mRNA splicing isoforms than lowly expressed 
genes (Kan et al., 2001). A study of genes that are highly represented by transcript data 
(that is, > 700 ESTs), showed that 99% of the genes are alternatively spliced (Modrek et 
al., 2001). Although some of this AS evidence could be false positives from sequencing 











transcriptome more comprehensively become available, it is possible that all multi-exon 
genes are indeed subjected to alternative splicing.  
 
False negatives are also attributed to features of specific mRNA transcripts. The unstable 
nature of mRNA sequences contributes to false negatives in the detection of alternatively 
spliced mRNA isoforms since ESTs are biased towards the genes with more stable 
mRNAs. The less stable mRNAs are poorly represented in the EST databases, especially 
if they are extracted from samples such as pancreatic tissues in which numerous RNAase 
enzymes are found to occur.  
 
The EST manufacturing protocol is commonly designed such that the start point of the 
EST generation protocol is controlled whereas the terminati n of the sequencing reaction 
is random. This creates a bias towards capturing of expression in the 3’ and 5’ ends of the 
genes and largely omitting the middle sections. In comparison to the 5’ end, the poly-A 
tail of the 3’ ends of mRNA sequences is an ideal sequence for targeting primers and 
hence most of the data is heavily biased towards ESTs that capture the 3’ ends. Full-
length cDNAs would be the most accurate in the detection of mRNA isoforms along the 
full length of the transcripts; however the number of cDNAs currently available is much 
less in comparison to ESTs. A recent study proposed a method that designs 5’ and 3’ 
primers and reiterates the process of designing primers and re-sequencing based on where 
the previous ESTs terminated resulting in the capturing of the cDNA clone insert along 
its entire length (Imanishi et al., 2004). This method holds great promise in making EST 
transcripts an even more attractive resource in effective deciphering of the transcriptome. 
 
ESTs only capture AS isoforms of genes that are expressed in tissues and cell-types and 
developmental stages that were used in constructing cDNA libraries. For example, 
despite the INI1 gene having over 100 ESTs in dbEST, novel mRNA transcripts are still 
being discovered (Favre et al., 2003). This is likely to be because ESTs in public 
















False positives could also be caused by contaminants, sequencing errors and ESTs 
capturing unspliced or partially spliced pre-mRNA which are still under-going the 
splicing process. For example, in unspliced or partially spliced pre-mRNA, introns could 
be falsely detected as intron retention events. In addition, various mechanisms discussed 
in the subsequent sub-section can also cause false positives. 
 
2.3.2 Other causes of false positives 
 
There are numerous other mechanisms and processes besides AS that result in the 
production of multiple mRNA isoforms. The AS spliced databases do not take into 
account all these false positives and therefore, their impact on these databases is currently 




RNA editing is a ubiquitous mechanism that occurs in all living organisms. It occurs 
post-transcriptionally and modifies the transcript by a single or multiple base insertions, 
deletions, conversions or substitutions (Niswender, 1998; Seeburg et al., 1998).  The 
insertions and deletions can be erroneously detected as alternatively spliced introns and 
exons. 
 
Random spliceosome errors 
 
Just like any other biological enzyme or molecule, the spliceosome can also make errors 
(Graveley, 2001). Such random errors in splice site recognition by the spliceosome can 
result in the expression of novel mRNA transcripts. The presence of numerous cryptic 
AG and GT di-nucleotides that exist in the vicinity of authentic splice sites are a major 











to authentic splice sites, the chances of slipping are increased substantially. Using mouse 
alternatively spliced cDNAs Chern et al., (2006) showed that the spliceosome slips 
occasionally particularly when AG or GT nucleotides exist close to the authentic splice 
sites. Such aberrant isoforms account for approximately 5% of AS isoforms in the public 
databases (Chern et al., 2006). 
 
External stress to cells 
 
Cells stressed as a result of heat, drastic pH changes or lack of oxygen in-vivo or in-vitro 
just before extraction of tissues can also lead to aberrant splicing. pH changes and lack of 
oxygen in-vivo can cause aberrant splicing by altering the distribution and sub-cellular 
localization of the enhancer and silencer trans acting factors  such as the hnRNP A1 and 
tra2 (Daoud et al., 2002). The ICH-1 gene is alternatively spliced depending on the 
concentration of the tra2 (Trasfomer-2) trans-acting factor. Brain ischemia (that is, 
restricted blood flow to the brain), results in a lack of oxygen which then alters the 
concentration of tra2 causing aberrant splicing in the brain (Daoud et al., 2002).  
 
Changes in temperature in-vitro can also result in aberrant splicing (Colot et al., 2005). 
Heat can interfere with mRNA conformation and thus can make cryptic splice-sites more 
accessible to the spliceosome in comparison to the authentic splice sites (Varani et al., 
1999). For example, a study on the CAD pre-mRNA transcript in hamster cells 
established that cryptic sites were activated and preferred when cells were heat shocked 
(Miriami et al., 1994). Cold has also been reported to induce retention of an intronic 
segment in the neurofibromatosis type 1 (NF1) mRNA (Ars et al., 2000). 
 
Such sensitivity of the mRNA splicing process to external physiological changes such as 
temperature and pH highlights the need to mimic physiological temperatures and to 
perform fast extraction of mRNA transcripts from tissue samples. Prolonged storage of 
tissue cultures or cell-lines and slow processing of mRNA transcripts from fresh tissue 
increases the chances of aberrant splicing and the capturing of such mRNA isoforms by 
EST transcripts or microarrays. Disregard of such in-vitro induced aberrant splicing could 











splicing especially of medical importance. For example in a genetic screening of the NF1 
gene, a cold induced partial intron retention event was erroneously interpreted as being 
associated to the NF1 disease (Ars et al., 2000).   
 
Alternative transcription initiation sites 
 
RNA polymerases initiate transcription after recognition of promoter sites. 
Approximately 18% of all human genes have been estimated to show evidence of 
alternative transcription initiation based on the presence of alternative promoter site usage 
(Landry et al., 2003). These alternative transcription initiation sites result in the 
generation of multiple mRNA isoforms in different cellular conditions such as tissue and 
developmental stages. The multiple mRNA isoforms generated from alternative 
transcription initiation are difficult to filter from mRNA isoforms produced through AS 
and thus inflate mRNA isoforms in the databases of alternatively spliced mRNA 
transcripts. 
 
Alternative transcription termination and polyadenylation  
 
After the termination of transcription during gene expression, the mRNA transcripts are 
cleaved followed by the addition of a poly (A) in a process known as polyadenylation. 
The poly (A) tail added to the mRNA transcript by the polyadenylation protects the 
transcripts from degradation and is required for export of the mRNA from the nucleus 
(Hunt et al., 2008; Ford et al., 1997). Variations in the poly (A) tail results in the 
production of mRNA isoforms from the same gene unit of variable length and activities. 
Numerous precursor mRNA transcripts have multiple alternative termination and 
polyadenylation sites (Shen et al., 2008). Alternative transcription, termination and 
polyadenylation are thus mechanisms that can spuriously inflate the number of mRNA 
















Alternative splicing is the splicing of mRNA in different ways from identical transcripts. 
The production of distinct mRNA isoforms from different alleles of the same gene is 
known as allele-specific splicing, detailed in the next section.  
 
2.4 Allele-specific splicing  
 
Accuracy in the AS process depends on precision in the determination of exon-intron 
boundaries, splicing out of introns and annealing on the exons (Krawczak et al., 2006). 
As indicated in section 1, a myriad of different regulatory rans- and cis-acting factors are 
required. Mutations that disrupt any of the trans- and cis-acting factors involved in 
splicing causing inaccurate recognition of splice sites or alterations in splicing efficiency 
can affect both mRNA splicing and alternative splicing (Cartegni et al., 2002), leading to 
allele-specific splicing (Nembaware et al., 2004). 
 
Cis-acting mutations can disrupt any of the core auxiliary elements specific to splicing 
(Figure 5). RNA structures have been shown to affect the distance between donor and 
acceptor sites, mutations that affect these structures can cause an increase in the distance 
between the splice site and enhancers reducing cross-talk between splicing factors  that is 
required for the splicing process (see section 2.1) (Libri et al., 1995). The number of 
elements which if mutated could result in allele-specific splicing events is also increased 
by the coupling of the AS regulation to the regulation of mechanisms such as 
transcription (Kornblihtt, 2007). Unlike mutations that disrupt trans-acting factors, cis-
acting mutations are easier to detect because they can be linked with much greater ease to 














Figure 5: An Illustration of possible positions at which mutations can disrupt splicing.  Part of the figure was adapted 
from Baralle and Baralle, 2005. 
 
Cis-acting mutations have several possible outcomes on splicing patterns, which include 
exon skipping, activation of cryptic splice sites and intron retention. Important 
determinants of the outcome of cis-acting mutations include, the presence of a strong 
acceptor or donor site in the close proximity of a destroyed splice site (Krawczak et al., 
2006), the type of cis-acting element affected (Cartegni et al., 2002; Krawczak et al., 
2006; Berget, 1995), and the splice site recognition model that is used to recognize the 
exon-intron junctions (Berget, 1995). In the absence of strong cryptic splice sites in close 
proximity to authentic splice sites, mutations that disrupt the exon definition could cause 
exon-skipping, while errors in intron definition are likely to cause intron retention. 
Mutations that affect recursive splice sites and i tra-splicing could lead to a variety of 
consequences which include truncated mRNA sequences. Knowledge of the consequence 
of a splicing mutation could be useful in predicting the phenotypic effect of an allele-
specific splicing event. 
 
2.4.1 Impact of allele-specific splicing on disease and 
pharmacogenetics 
 
Cells have evolved complexes that recognize and eliminate aberrantly spliced mRNA 
isoforms. If translated into protein, mRNA transcripts can have a negative gain of 
function which is likely to lead to disease. A PTC located at least 50 bps upstream of the 
last exon-exon junction, triggers the NMD pathway (Lewis et al., 2003) which then 











degrading the truncated transcripts, causes skipping of the PTC containing exon. This 
pathway is now commonly referred to as nonsense associated splicing (NAS) (Wang et 
al., 2002). Interestingly, in addition to biological screens for PTC containing transcripts, 
there seems to be yet another surveillance system that eliminates transcripts that have lost 
their stop codons (Frischmeyer et al., 2002; Maquat, 2002). 
 
However, even with such proofreading mechanisms, some of the allele-specific splicing 
events slip through and become part of the cell’s transcriptome. Allele-specific splicing 
can cause both qualitative and quantitative changes to splicing (Wang and Cooper, 2007) 
(Chapter 1). Both qualitative and quantitative allele-specific splicing changes can lead to 
individual-specific variations in disease severity, alter viral susceptibility and 
pharmacogenetic effects (Table 2) (Wang and Cooper, 2007). 
 
Mutations that cause splicing changes have even been suggested to be the most frequent 
cause of human disease (Lopez-Bigas et al., 2005). Most of these changes are toxic to the 
cell (Wang and Cooper, 2007; Faustino and ooper, 2003). However, some disease-
causing qualitative changes induced by aberrant splicing mutations might not be novel 
mRNA splicing variants but could be AS events that get expressed in the wrong context. 
For example, when embryonic and neonatal isoforms of the dystrophy gene are expressed 
in the adult myotonic dystrophy tissues, diseases such as myotonia and insulin resistance 
can result (Ranum and Copper, 2006). 
  
Drug efficacies, clearance rates, and responses even for approved drugs are highly 
variable between individuals with different genotypes (Bracco and Kearsey, 2003). 
Adverse drug responses are a leading cause of death particularly in developed countries. 
One of the aims of the pharmacogenetics field is to define the functional consequences of 
polymorphisms that have been linked to pharmacogenetic variations. Such information is 
required to design drugs with improved specificity and sensitivity. Numerous 
polymorphisms of pharmacogenetic relevance affect drug response by causing the 












Table 2: Splicing SNPs that affect disease and pharmacogenetics. We have tabulated several SNPs from published 
literature that lead to disease or pharmacogenetic variations through an effect on splicing based on the naming 
convention of SNPs in dbSNP. Currently, the dbSNP naming convention is widely used to document and annotate any 





































Qualitative An increased risk of 
adverse drug reactions 
in patients treated with 
the thiopurine drug 
azathioprine. 




Acceptor Qualitative Susceptibility to type 1 
diabetes and viral 
susceptibility 
(Field et al., 
2005; 
Bonnevie-







ESE Qualitative Carbohydrate-deficient 
glycoprotein syndrome 
(Vuillaumier-





rs688 ESE Qualitative Increased cholesterol 
in pre-menopausal 
women 
(Zhu et al., 
2007) 
 
SCN1A rs3812718 Donor site Quantitative Possibly influence 









rs41293511 ESE Qualitative 
 
Breast cancer (Fackenthal et 
al., 2002) 
 
BTNL2 rs2076530 Donor site Qualitative Sarcoidosis (Valentonyte 
et al., 2005) 
 
2.4.2 Detection of allele-specific splicing  
 
Detection of allele-specific splicing events and/or their causal mutations is not always 
trivial. The number of splicing regulatory elements which if disrupted can lead to 











systems. Furthermore, since some splicing events appear to be coordinated, the mutations 
that affect splicing in one region of the gene can also affect splicing patterns in a different 
region (Fededa et al., 2005) and this complicates the detection of splicing mutations even 
more. The complex nature and myriad of regulatory elements involved in splicing greatly 
increases the number of locations at which mutations can affect precision and efficiency 
of the spliceosome. 
 
2.4.2.1 Ab initio prediction tools 
 
One of the most widely used databases of heritable mutations is dbSNP (Sherry et al., 
2001). Currently, dbSNP houses more than 10 million human SNPs. The availability of 
such large sequence variants coupled with the growing appreciation of the need to 
discover splicing regulating cis-acting elements prompted an increase in the of use ab 
initio prediction tools (Table 3). Such tools can be applied to publicly available databases 
of genomic variants such as dbSNP, which greatly enhances the characterisation of the 
functional impact of SNPs on disease. Numerous databases have taken this approach by 
scanning for splicing mutations in dbSNP using ab initio tools such as  PupaSuite (Conde 
et al., 2006) and PolyMapr (Freimuth et al., 2005). More recently, the SNAP database has 
performed a very comprehensive scan by using six different ab initio tools on dbSNP 
entries (Li et al., 2007). 
 
For each allelic version of the transcript, the ab initio tools predict the likely impact of the 
sequence variants on the strength of the splicing regulatory element. Usually a score is 
assigned which is supposed to correlate with splicing strength (Baralle and Baralle, 
2005). Scoring systems are commonly based on comparing allelic versions of a given 
sequence to a cis-element consensus sequence. A splicing mutation that changes the 
regulatory element from its consensus altering the splicing scores is likely to lead to 
aberrant splicing.  
 
Although consensus sequences were highly popular, dependencies and compensatory 











Matrices based on nucleotide frequencies do not always include such dependencies. 
Improvements on the ab initio algorithms and tools include incorporating dependencies 
between the nucleotides within regulatory elements (Churbanov et al., 2006; Yeo and 
Burge, 2004). Such an approach seems promising, one of these algorithms, the maximum 
entropy, that takes into account site to site dependencies in donor and acceptor sites was 
recently reviewed as one of the best performing tools among five algorithms in predicting 
the impact of a mutation on 3’splice sites (Vorechovsky, 2006). 
 










http://www.fruitfly.org/seq_tools/splice.html (Reese et al., 1997) 
Donor and 
acceptor 








ESEFinder http://rulai.cshl.edu/tools/ESE/ (Cartegni et al., 
2003) 






(Wang et al., 2004) 
 
Branch site Branch Site 
Analyzer 
http://ast.bioinfo.tau.ac.il/BranchSite.htm (Kol et al., 2005) 
 
 
The computational tools developed for predicting the impact of a sequence variant on 
splicing have had numerous successes (Eng et al., 2004; Vorechovsky, 2006). However, 
ab initio tools should only provide the first point of exploration when accessing the 
impact of a mutation on splicing (Baralle and Baralle, 2005). There are many instances 
where splicing scores fail to predict accurately the impact of a mutation on splicing 
(Carothers et al., 1993; Buchroithner et al., 2004). For example, a mutation in the LAMB3 
gene that creates a new splice site with a splice score of 68.6, is preferentially used over 
the wild type splice site, even though the wild type splice score has a much higher splice 
score of 92.2 (Buchroithner et al., 2004) using the scoring system of Shapiro and 











located in close proximity to the splice site. Furthermore, some changes that abolish one 
ESE could create a functionally compensating ESE at the same location (Cartegni et al., 
2002).  
 
Currently, there is no perfect method to estimate the false discovery rate of the ab initio 
tools and hence functional assays are thus required to confirm putative splicing mutations 
inferred from these computational analyses. The SNAP curators have realized the 
importance of experimental validations and have thus designed a web browser that 
facilitates the designing of primers for further experimental validation based on the 
putative splicing mutations in their database (Li et al., 2007).  
2.4.2.2 Hybrid minigene assays 
 
Hybrid minigenes are constructs of plasmids that contain a short RNA fragment of a gene 
under-study. About 20 years ago a minigene was first used to provide concrete evidence 
of alternative splicing and the need for the extra cis-regulatory elements such as 
enhancers and silencers in controlling splicing in addition to the canonical donor and 
acceptor sites (Vibe-Pedersen et al., 1984). Minigenes have since been altered for 
assaying splicing cis-acting mutations.  For biallelic mutations two minigenes are created, 
for the wild-type and mutated alleles (Figure 6). The hybrid minigenes are then 
transfected into appropriate cell lines followed by RT-PCR and gel electrophoresis. 
Minigenes are suitable for the capturing and visualization of all allele-specific splicing 
events, but exon skipping seems to be the most suitable.  
 
The minigene assays are quite popular since the affected tissues are not required and one 
can identify the causal mutation of observed allele-specific event without the need for 
human samples. However, this lack of tissue is one of the main disadvantages of using 
minigenes. As highlighted in section 1, AS is sometimes coupled to transcription and 
translation. Therefore, minigene assays are unsuitable for analysing allele-specific 
splicing events that are caused by complex interactions between multiple mutations or 
elements located far from the affected site. Minigenes are also not ideal for quantitative 











experiments to suit this task (Hull et al., 2007). By using florescence to illuminate the 
exon skipped event, minigenes were used to detect the levels of skipping taking place 
(Hull et al., 2007). Furthermore, instead of performing normal RT-PCR (see Figure 6), 




Figure 6: Detection of cis-acting mutations that cause splicing differences or their allele-specific products. A 
hypothetical example of a splicing mutation that disrupts a splice acceptor leading to an exon skipping event is used to 
illustrate how it can be detected or predicted using different methods A) ab initio prediction. B) Primers can be 
designed that target the allele-specific skipping event. Primers are shown as arrows in the figure. Gel electrophoresis 
can clearly indicate the skipping of the exon from the different alleles. C) Minigene which encompasses the splicing 
mutation and exon skipping events can be designed to prove that the G to A mutation leads to aberrant splicing. D) 
Exon arrays can be designed to illustrate the allele-specific skipping event. Probes are created for the exons of the 
affected gene. Cells from different individuals are then genotyped. Differences in exon expression from the different 
individuals can then be noted on the array platforms based on the binding affinities of the cell samples to the array 




The first study that used microarrays for the detection of aberrant splicing was performed 











measure expression intensity in normal and wild type tissue and used to predict allele-
specific splicing events. However, the main disadvantage was that the arrays could only 
be used for small-scale studies until the availability of genotyped cell lines from the 
HapMap dataset (The International HapMap Consortium, 2005). 
 
The HapMap project was borne out of the need to further characterize the millions of 
SNPs discovered from the Human Genome Project (The International HapMap 
Consortium, 2005). The HapMap consortium genotyped 269 individuals, whose ancestors 
originated in Africa, Asia and Europe. The availability of the genotyped cell-lines from 
the HapMap consortium has marked a turning point in the use of arrays for the detection 
of allele-specific splicing (Nembaware et al., 2008; Kwan et al., 2007; Kwan et al., 2008; 
Hull et al., 2007).  Using the HapMap genotyped cell-lines on the Affymetrix exon array 
platforms allows for large-scale association of alternative splicing events to 
polymorphisms and thus, the detection of allele-specific splicing (Chapter 5). However, 
such analyses do not prove a causal relationship between the SNPs and the allele-specific 
splicing events. Further experiments such as minigene assays are required to prove such 
causality. 
2.4.2.4 Evaluation of functional assaying methods  
 
The use of each method is associated with its own advantages and disadvantages (Table 
4). Some of the methods do not actually detect the casual mutation; they can only prove 
association of a mutation to an allele-specific event. The most appropriate allele-specific 
detection method would be one that replicates the cell’s environment as accurately as 
possible while allowing for the detection of allele-specific qualitative and quantitative 
splicing changes as well. However, this is exceptionally difficult for human studies. 
Because each method is not perfect, the most ideal would be an integrated analysis of 
















Table 4: Evaluation of methods for the detection of cis-acting splicing mutations using binary notation 
Methods Association Causality Qualitative 
 
Quantitative Tissue source 
required 
RT-PCR 1 0 1 1 (only for 
qRT-PCR) 
1 
Minigene 1 1 1 0 0 
Ab initio 0 1 1 0 0 
Exon-Arrays 1 0 1 1 1 
 
2.5 Concluding remarks  
 
ESTs and microarrays have radically transformed the pace at which alternatively spliced 
mRNA isoforms are detected and the rate of discovery and characterization of AS 
regulatory networks. The growing number of characterized splice site recognition models 
and splicing regulatory networks allows for a greater ease in the discovery of allele-
specific splicing events. Although there is a substantial improvement in the methods used 
for the detection and characterization of allele-specific splicing, there is currently no 
perfect method. Continual improvements in methods that detect allele-specific splicing 
will bring an improvement in our understanding of human variation in disease, 

























Discovery of sequence variants associated with inter-individual phenotypic differences 
remains one of the most long-standing challenges in genetics. Studies based on 
transcribed Single Nucleotide Polymorphisms (SNPs), are increasingly becoming popular 
in genotype-phenotype associations since such SNPs can potentially alter protein 
sequences and/or affect gene expression patterns. In addition, transcribed SNPs are also 
ideal markers for unknown causal mutations that lead to allele-specific gene expression 
or allele-specific splicing. A clean dataset of transcribed sequence polymorphisms and 
their genotypes would therefore greatly facilitate studies aimed at characterising allele-
specific gene expression/ allele-specific splicing. However one major drawback is the 
large number of chromosomes required for genotyping in-order to obtain reliable 
information. The use of sequence variants encoded in millions of publicly available 
Expressed Sequence Tags (ESTs) sequenced from a diverse range of ethnic groups, offers 
an affordable and accelerated strategy for genotyping and studying sequence variants. 
The scarcity of resources that allow users to harvest and visualize corresponding alleles 
from ESTs is a key obstacle to studying allele-specific gene expression and allele-specific 
spling. We have used genomic locations of SNPs and ESTs from the UCSC genome 
databases to determine the location of the SNPs on ESTs. We report a database, 
snp2estmap, of the nucleotides present at the polymorphic positions on EST sequences 
for 532 860 SNPs that could be mapped to 4 461 202 ESTs. To facilitate other studies, an 
interface was developed to make snp2estmap searchable via the internet at 
http://mancala.cbio.uct.ac.za/splicing. In addition, potential applications for this resource 













As a direct consequence of large-scale sequencing projects of cDNA clone libraries, 
publicly available databases of Expressed Sequence Tags (ESTs) have grown in size 
exponentially. Comparative evaluation of the current version of dbEST (February 2008) 
and the December 1991 version showed almost a 500 fold increase in the total number of 
dbEST transcripts. According to the pioneers of the EST sequencing protocol, the 
primary use of EST data was to facilitate rapid and inexpensive human gene discovery 
(Adams et al., 1992).  The usefulness of such transcripts continues to expand mainly due 
to the diversity of genotypes, tissue-types and disease states represented within EST 
databases. Due to these attributes ESTs have become invaluable for the identification of 
gene expression variation across tissues (Megy et al., 2002), cancers (Aouacheria et al., 
2006) detection of alternatively spliced isoforms (Lee and Wang, 2005; Kim et al., 2007) 
and for the discovery of   transcribed single nucleotide polymorphisms (SNPs) (Buetow 
et al., 1999; Picoult-Newberg et al., 1999).  
 
It is well known that the accuracy of SNP analysis based on ESTs could be greatly 
compromised by the error prone nature of these single pass transcripts (Nagaraj et al., 
2007). Contrary to this argument, after implementation of pre-processing stages that 
reduce noise in transcript data, several lines of evidence  have established EST data as a 
robust source of SNP allelic information (Buetow et al., 1999; Hayes et al., 2007). 
Experimental validation has indicated high accuracy levels of at least 80% in SNPs mined 
from ESTs (Buetow et al., 1999; Kota et al., 2003). Further validation arises from the 
consistency in the distribution of SNP allele frequencies between publicly available 
transcript data and other independent studies (Sunyaev et al., 2000), including the CEU 
population in the HapMap datasets (Ge et al., 2005). Using 2678 SNPs genotyped from 
EST data, a correlation co-efficient of 0.7386 was obtained when allele-frequencies 
estimated from the EST data and the CEU population were compared (Ge et al., 2005). 
Due to the geographical locations of the largest EST sequencing projects, it is not 
surprising that the EST data reflect the CEU population more than any of the other 












The prevalence of allelic differences in gene expression in human is high (Lo et al., 
2003). Several studies have suggested that the regulation of gene expression is mainly 
controlled from within the 3’ and 5’ untranslated regions (Rockman and Wray, 2002; 
Mossner and Riederer, 2007; Cowles et al., 2002). Due to the pre-existing bias of ESTs 
towards 3’ and 5’ gene regions, there is a high probability that most SNPs that cause 
allelic differences in gene expression are over-represented in the transcript data. Beyond, 
the EST-based SNPs actually causing allelic variations in gene expression, their 
usefulness can be extended to ascertain the presence of an unknown cis-acting regulatory 
variant based on the principle of linkage disequilibrium (Pastinen et al., 2004; Knight, 
2004).  This attribute of SNP information derived from ESTs has led to several 
investigations aimed at understanding allele-specific expression for cases where cis-
acting variants are difficult to locate (Seoighe et al., 2006; Nembaware et al., 2004; Ge et 
al., 2005), or even unknown epigenetic factors that lead to imprinting (Seoighe et al., 
2006; Yang et al., 2003). 
 
The versatile nature of EST-derived SNP data is further demonstrated by their use in 
mutational and selection studies (Sunyaev et al., 2000). In fact, the first large-scale 
investigation of the pattern of selection and mutation in human was conducted on EST-
based SNP data (Sunyaev et al., 2000). Allele frequencies from EST data were 
successfully used to measure selection at degenerate, non-degenerate sites and in the 5’ 
and 3’ untranslated regions of human genes (Sunyaev et al., 2000).  
 
For genome-wide studies based on EST-derived SNPs, it is often difficult and time-
consuming to determine SNP alleles from publicly available databases. A resource of pre-
extracted SNP alleles from EST data would greatly facilitate further research. There are 
several databases that present SNP alleles extracted from ESTs (Hawken et al., 2004; 
Guryev et al., 2005). However such studies focus only on transcripts from model 
organisms such as rat (Huntley et al., 2006) zebrafish (Guryev et al., 2005; Huntley et al., 
2006), and cow (Hawken et al., 2004). EST-derived SNP databases that focus on human 
data are not comprehensive. They do not make use of all publicly available datasets 












Currently no genome-wide resource exists that has pre-extracted SNP allele information 
from ESTs. By utilizing SNP and EST alignments to the human genome from the 
University of California Santa Cruz (UCSC) genome browser database (Hinrichs et al., 
2006), we have created a resource that enables users to query a database using SNP 
accessions from dbSNP or EST Genbank accessions, returning among other things 
potentially useful annotations in addition to the SNP alleles represented on the ESTs. We 
also highlight how this resource can be useful to the scientific community at large by 
indicating the various ways in which this resource has been extensively used throughout 
this thesis. 
 
3.2 Data and methods  
3.2.1 Data 
 
The UCSC genome browser database provides annotation tracks (Hinrichs et al., 2006), 
consisting of tables of objects pre-aligned to genomic sequence. We downloaded SQL 
tables of pre-computed EST and SNP genomic locations from the UCSC annotation 
tracks version hg17, which were based on NCBI genome assembly version 36 (Hinrichs 
et al., 2006). dbSNP has multi-nucleotide substitutions, indels and bi-allelic 
polymorphisms commonly referred to as SNPs. We choose to focus only on SNPs as they 
form the majority of sequence variants in the dbSNP database and are easiest to genotype 
from transcript data. 
  
Human EMBL flat files release 89 was downloaded from the EBI ftp server 
(ftp://ftp.ebi.ac.uk). A total of 7,222,889 million transcript data with cDNA clone library 
annotations were extracted from the EMBL flat files using Perl scripts.  
 
3.2.2 Quality control 
 
dbSNP is the largest and the most widely used database of genomic variation. In addition 











as JSNP (http://snp.ims.u-tokyo.ac.jp/), also contribute to dbSNP. Although the overall 
quality of dbSNP entries is considered to be very high, some of the SNPs are of poor 
quality due to sequencing artifacts (Platzer et al., 2007). Furthermore, many genes in the 
genome are part of large gene families. SNP sequences may have multiple high-quality 
alignments to the genome. To reduce the impact of paralogous sequences and the impact 
of sequencing errors we removed SNP entries that mapped multiple times to the genome. 
 
ESTs can also map ambiguously to the genome due to the many paralogs that exist in the 
human genome, sequencing errors and sequence contaminants. To alleviate the impact of 
paralogous sequences and sequencing errors, ESTs that mapped multiple times to the 
genome were also discarded. In order to lower the influence of chimeric sequences and 
contaminants from non-human sequences, we only considered ESTs that mapped with at 
least 90% of their total length to the genome.  
 
3.2.3 Extraction of SNP alleles from ESTs 
 
Perl scripts were designed to detect all SNPs found within genomic boundaries of ESTs. 
We then used SNP and EST genomic coordinates from UCSC to extract the 
corresponding SNP alleles from each polymorphic site along the EST. A flow-diagram in 




























Figure 1: Flow diagram of our method for the extraction of SNP alleles from expressed transcripts. We have illustrated 
using SNP rs2295680 and only 3 transcripts how the snp2estmap mysql database was created. Entries that map 
ambiguously to the genome in the UCSC EST and SNP tracks are discarded. Genomic positions of SNPs located within 
ESTs are extracted and used to determine the position and allele of the SNP on the EST.  
 
3.2.4 eVOC ontologies  
 
The curators of eVOC (Kelso et al., 2003) developed four ontologies using a highly 
comprehensive and controlled vocabulary to describe human gene expression data. The 
ontologies include Anatomical System, Cell Type, Pathology and Developmental Stage. 
Thus far, the eVOC database has annotated 7016 cDNA libraries from dbEST.We 
downloaded over 6000 cDNA libraries annotated according to Pathology from eVOC 











annotated as originating from cancer or normal tissues were considered further. These 
cancer annotations were then used to classify ESTs into categories cancer or normal 
tissues.  
 
3.3 Results  
3.3.1 A database of SNPs mapped to ESTs 
 
Based on UCSC transcript alignments to the human genome, we created a database of 
532,860 SNPs that map to ESTs. Though deletions/insertion variants and multi-
nucleotide substitutions exist, our analysis was based only on bi-allelic SNPs The EST-
based SNPs represent approximately 5% of all SNPs that mapped to the genome (Table 
1). Some SNPs that were located within ESTs could not be allocated alleles because of 
masking at the exact SNP locations in the EST transcripts or unavailability of the 
transcript data due to incongruence in the updating of the EMBL database of transcript 
data and UCSC genome browser database. ESTs are contaminated with vector sequences 
during the experimental procedure. Repetitive elements are also frequent in EST data, these 
include ALU, SINE and LINE elements. EMBL transcript data is put through a masking 
process to screen ESTs for such contaminants. This masking step is evident in the 
transcript data where strings of NNNs’ have replaced the repeats and vector sequences.  
 
A significant limitation of this study and many other similar studies is that many SNP 
alleles extracted from EST data potentially result from poor quality sequence data that is 
characteristic of single-pass sequences (see Chapter 1). To reduce the impact of transcript 
noise on our results, only ESTs that mapped with at least 90% of their sequence length to 
the genome were considered. Part of the noise in EST data is from chimeric sequences 
which result from sequence fragments from two separate cDNA libraries that erroneously 
ligate into one transcript. Non-human sequences are also likely to be filtered out using the 
criterion of enforcing that most of the transcript maps to the genome. 
 
Paralogous genes occur frequently in human and can cause SNPs and ESTs to map 











to the genome (Table 1). The fragmentary nature of the EST and SNP data could also 
result in these sequences having multiple high similarity matches to the genome purely by 
chance alone, leading to inaccurate EST or SNP to genome mappings.  
  
Table 1:  Summary of the processing of data for snp2estMap 










3.3.2 Annotation of ESTs using eVOC 
 
Based on the eVOC Pathology cDNA library annotations (Kelso et al., 2003) we 
categorised 4729 libraries as cancer libraries and 2232 as non-cancer libraries. We used 
the pathology annotated cDNA libraries to integrate the eVOC gene expression 
information with the SNP to EST mappings. The integration of the database of SNPs 
mapped to ESTs with eVOC enables researchers to test for associations between cancer 
expression states and SNP alleles represented on ESTs.  
 
3.3.3 Web interface 
 
We created a simple interface to our MySQL database which is powered by CGI and Perl 
scripts, available at http://mancala.cbio.uct.ac.za/~victoria. Using SNP rs2295680 found 















Figure 2: A screen-shot illustrating the web-pages that can be used to query the snp2est database and the output page 
using the SNP rs2295680. The SNP and EST identifiers are linked to their original sources dbSNP and dbEST 
respectively. 
 
3.4 Discussion  
 
Major bottlenecks in the application of SNP allele information encoded within publicly 
available EST data are the integration of at least two databases dbSNP (Sherry et al., 











such investigations we have provided a resource whereby researchers can obtain pre-
computed allelic information of SNPs that map to ESTs.  
 
Snp2estmap is likely to contribute significantly to allele-specific gene regulation studies.  
Recently, it has become well established that SNPs located within coding regions can 
have dual effects; modifying protein sequences and/or causing allelic differences in gene 
expression (Cartegni et al., 2002). It has now become imperative to assess all coding 
SNPs with regard to their impact on gene regulation regardless of their impact on protein 
sequences. The EST-based SNPs could disrupt regulatory elements located within genic 
regions. Such SNPs can influence gene expression by modifying mRNA transcription 
binding sites (Mossner and Riederer, 2007) or even by altering mRNA splicing patterns 
(Fairbrother et al., 2004; Cartegni et al., 2002).  
 
Allelic imbalances in expression are highly prevalent in human (Lo et al., 2003), and 
contribute to a wide range of phenotypic differences which include depression in the 
highly prevalent Parkinson’s disease patients (Mossner et al., 2001), and susceptibility to 
cancers (He et al., 2005). Besides actually causing allelic differences in gene expression, 
the use of transcribed SNPs as genetic markers in detecting allelic differences in gene 
expression is now well established. Some cis-acting variations that alter gene expression 
are likely to be located in intronic regions making transcribed SNPs potential highly 
informative markers if they are in linkage disequilibrium with the unknown regulatory 
variants genetic or epigenetic in nature (Ge et al., 2005; Pastinen et al., 2005).  
 
In comparison to EST-based SNP analysis, there are several high-throughput methods 
capable of high precision and accuracy for studying allelic imbalances in gene expression 
(Kwok, 2001). Some of these methods include use of oligonucleotide arrays that are 
specifically designed to quantify allelic gene expression differences (Pant et al., 2006. 
However, microarray based studies can be expensive, laborious and can be limited by the 
unavailability of tissue samples. ESTs offer an affordable and convenient alternative for 
quantifying allelic gene expression differences using existing publicly-available data. 











transcripts sampled from many cDNA libraries originating from different individuals. 
Unlike other captured data types which only capture a small number of tissue and disease 
states, human EST databases currently represent expression states in thousands of 
different tissues and disease states. Tissue specificity in allele-specific expression is 
possible (Cowles et al., 2002), and ESTs offer an opportunity to detect this. There are 
also several expression states represented in EST data which can be accessed through 
carefully designed controlled vocabularies (Kelso et al., 2003). 
 
Transcribed SNPs detected from EST data have emerged as important means to assess 
relationships between genotypes and disease phenotypes (Aouacheria et al., 2007). The 
normalization and subtraction (Bonaldo et al., 1996) procedures that were developed to 
improve transcript sampling of lowly expressed genes may increase the chances of 
capturing rare alleles which are likely to be deleterious mutations. ESTs are also 
sequenced from different pathological states, with a substantial bias towards cancerous 
tissues. The integration of cDNA libraries annotated according to the cancer status of the 
tissue from which they were sequenced using eVOC ontologies (Kelso et al., 2003), with 
the snp2estmap database enables researchers to search for associations between SNP 
alleles and cancer expression states.  
 
The use of snp2estmap has led to a wide-range of studies specifically for this thesis. 
Through integration of the EST data with other annotations such as splicing and the 
pathology state of cDNA libraries we enhanced the utility of snp2estmap. Table 1 lists 
some of the studies in which we have applied data from snp2estmap. This resource will 


















Table 1:  Studies in this dissertation that were based on the snp2estmap database 
Aim of study Additional Data Chapter Publication 
Detecting allele-
specific expression 
and  imprinting 
Pathology annotations from 
eVOC 





mRNA splicing patterns 
from ASAPII (The 
Alternative Splicing 
Annotation Project II) 
(Kim et al., 2005) 





mRNA splicing patterns 
from the ASAPII database 




A future prospect is to expand this resource to encompass as many organisms as possible. 
In Chapter 6, a similar database was also created and used to analyse strain-specific 
splicing in mouse. Given that most organisms have varying densities of SNPs some of 
which are linked to their virulence in the case of disease causing micro-organisms (Spatz 
and Silva, 2007) or variations in milk quality in sheep (Pirisi et al., 1999), identifying 
SNP alleles represented on the EST transcripts from many different organisms would 




























Alternative pre-mRNA splicing is common in multi-cellular organisms, and is estimated 
to affect 70% of human multi-exon genes. However, high estimates of the prevalence of 
alternative splicing are based on methods that are incapable of discriminating between 
mRNA isoforms due to alternative splicing and mRNA isoforms that result from 
polymorphisms that affect splicing. Although many examples of genes that are spliced in 
an allele-specific manner have been reported in the literature, no comprehensive genome-
wide estimates of the proportion of alternatively spliced genes that are affected by such 
polymorphisms have been carried out. Based on an integrated analysis of the dbSNP, 
dbEST and ASAP databases, we find that alternative transcript isoforms are non-
randomly associated with closely linked single nucleotide polymorphisms. From the 
observed level of association between transcript isoforms and single nucleotide 
polymorphisms, we estimate that 21% of alternatively spliced genes are affected by 
polymorphisms that either completely determine which form of the transcript is observed 
or alter the relative abundances of some of the alternative isoforms. We provide a 
conservative lower bound of 6% on this estimate and point out that alternative splicing of 
a gene cannot be confirmed with certainty unless more than one alternative mRNA 















The widely accepted definition of alternative splicing is that it is a process which 
produces different mature mRNA sequences from a single pre-mRNA transcript (Lopez, 
1998; Graveley, 2001). However, polymorphic versions of genes can also give rise to 
different mRNA isoforms, (which we shall refer to this as allele-specific splicing here-
after), which can easily be erroneously categorized as products of alternative splicing. 
Numerous examples of allele-specific splicing have been reported in the literature 
(Krawczak et al., 1992; Khan et al., 2002; Cartegni et al., 2002; Liu et al., 2001). Even 
transcripts that differ by just one single nucleotide polymorphism (SNP), can potentially 
produce different mRNA isoform if the mutation disrupts crucial splicing regulatory 
elements. Heritable point mutations that abolish the splice donor and acceptor sites can 
lead to activation of cryptic splice sites or promote exon skipping events (Spritz et al., 
1981). More intriguing are recent reports that have shown that coding polymorphisms 
whether nonsense, missense or silent can alter splicing patterns by causing exon skipping 
events if they disrupt splicing enhancer or create silencer elements (Cartegni et al., 2002). 
The participation of coding sequence variants in the regulation of splicing adds an extra 
class of previously disregarded mutations when evaluating allele-specific mRNA 
isoforms. Given the growing number of publications that report allele-specific splicing 
events, it is surprising that the contribution of polymorphisms to transcript variation is 
frequently overlooked and remains unquantified.  
 
Allele-specific splicing can involve not only qualitative changes to mRNA isoforms but 
also quantitative differences in relative isoform abundances (Buchner et al., 2003; 
Cartegni et al., 2002). Qualitative changes involve introduction of novel mRNA isoforms 
with altered exons, whereas quantitative changes, involve alteration of the relative 
abundances of pre-existing alternatively spliced mRNA isoforms (Buchner et al., 2003). 
Such structural and dosage alterations often have drastic effects on protein functions. In 
fact, candidate genes influencing susceptibility to complex diseases such as cancers, have 
                                               
This chapter is presented in the context of the literature as it was when we undertook and published the 











been found to produce allele-specific mRNA isoforms which differ between normal and 
affected individuals (Khan et al., 2002). The contribution of natural genetic variations to 
the diversity of splice isoforms should therefore be investigated and not overlooked as 
this holds great promise in contributing to our understanding of diseases and 
enhancement of human health. 
 
Most databases of alternatively spliced transcripts are detected based on inconsistencies 
in alignments of ESTs (Expressed Sequence tags) (Modrek et al., 2001; Kim et al., 2005), 
which are sampled from a diverse range of populations. ESTs are rich in polymorphisms - 
50% of ESTs have been reported to be highly polymorphic (Picoult-Newberg et al., 
1999). However, the current databases of AS transcripts have so far not distinguished 
between true alternative splicing and transcripts that arise from polymorphic versions of 
the genes. In consequence, the contribution of such allele-specific splicing to the current 
estimates of human multi-exon genes that are alternatively spliced is unknown. 
 
Krawczak et al., (1992), estimated that 15% of human genetic disorders attributable to a 
single gene involve aberrant splicing caused by single nucleotide mutations. This 
estimate was based on mutations located in the canonical donor and acceptor sites. 
Adapting the method employed by Krawczak et al., 1992 to estimate the prevalence of 
allele-specific splicing in human, would lead to a gross underestimate. Mutations that 
affect splicing are not restricted to the highly conserved GT and AG donor and acceptor 
sites, and these represent only a small fraction of mutations that could potentially alter 
splicing efficiency (Chapter 2). Therefore, estimates which are not based on counts of 
splicing mutations are needed to quantify the influence of sequence variants splicing. 
 
We developed an alternative approach for the estimation of allele-specific splicing which 
is based on the principle of linkage disequilibrium between exonic SNPs observed on 
ESTs and unknown splicing regulatory SNPs. We have used ESTs that can be mapped 
both to SNPs and alternatively spliced isoforms to estimate prevalence of allele-specific 
splicing in ASAP, a database of alternatively spliced genes (Modrek et al., 2001). 











instances, they can be in tight linkage disequilibrium with a mutation that affects splicing 
patterns, which in most instances is located within intronic regions. However the 
approach is valid even if the observed exonic SNP is the cause of the allele-specific 
splicing. We propose a sequential mutation model see Figure 1, in which the two separate 
linked mutations occurred in an unknown order. In this model, the more recent 
polymorphism will always be found in association with a single form of the earlier 
polymorphism. If one polymorphism results in qualitative allele-specific splicing and the 
other is detectable as an exonic SNP, then this would mean that one combination of 
transcript and SNP should never be present in EST databases. On the other-hand if 
polymorphisms do not affect the transcript isoform that is observed, then the choice of 
transcript isoform should be independent of the SNP allele and all four isoform/SNP 
combinations could occur in ESTs. 
 
 
Figure 1: The sequential model of mutations that could give rise to associations between a SNP and alternate isoforms 
of a gene. One isoform has a skipped exon shown in blue while the major isoform retains the exon A). The SNP 
mutation occurred first, followed by a mutation that leads to an exon skipping event. B)  In this scenario, a splicing 
mutation that causes skipping of the exon occurs first followed by the SNP mutation which is observed in the EST 
transcripts. C). A premature termination codon (PTC) in a cassette exon (blue). The PTC polymorphism is linked to an 
exonic SNP elsewhere on the gene, resulting in nonsense-mediated decay of the longer isoform from the allele 











4.2 Data and methods 
 
Pre-computed EST and SNP genomic locations were downloaded from the UCSC 
Genome Browser (Karolchik et al., 2003) which is based on the NCBI genome assembly 
35 (Hubbard et al., 2002). ESTs and SNPs that mapped onto more than one genomic 
position were discarded to avoid spurious EST to SNP matches from paralogous 
sequences and sequence contaminants. If multiple alleles were observed at a particular 
SNP position, only the two most common alleles were considered further. The SNP-EST 
mapping procedure has been described in detail in Chapter 3, based on a more recent 
version of the UCSC genome data. 
 
ASAP (Modrek et al., 2001) a database of alternatively spliced gene clusters, was 
downloaded. This data included short sequence fragments from alternatively spliced exon 
junctions associated with Unigene clusters. We mapped splice junctions involved in 
alternative splicing to EST sequences from the same Unigene cluster by scanning the 
ESTs for exact matches to the splice junctions. 
 
4.2.1 Data matrices 
 
We counted the numbers of EST representing each isoform/SNP combination in a 2X2 
data matrix where the columns correspond to transcript isoforms and the rows correspond 
to SNP alleles for a particular cDNA library. Figure 2 illustrates how matrices were 
created with data from the RPNC4/RBM23 gene. In order to eliminate potential bias 
resulting from multiple ESTs derived from the same tissue sample, we restricted the 
matrices to a single EST per clone library per SNP allele. To estimate the prevalence of 
allele-specific isoforms, only one SNP and one splice junction pair per Unigene cluster 
was considered as multiple splice junctions and SNPs from the same gene may not be 
independent. The chance of detecting polymorphic splice isoforms which are expressed at 
very low frequency was increased by selecting the rarest splice junction and a highly 














Figure 2: A) Illustrated example of allele-specific isoforms detected in the RNPC4/RBM23 gene.  ESTs supporting 
either the major or minor isoforms are shown above the genomic sequences. ESTs consistent with the major transcript 
isoform are shown on the left while ESTs consistent with the minor isoform with a skipped exon 6 are shown on the 
right. 10 ESTs support the skipping of exon 6, all of which have a G at a SNP site in exon 1. Of the ESTs from 
transcripts that include exon 6, five have a G at the polymorphic site and 26 have T at this site. B) A data matrix 




We carried out simulations to model the distribution of transcript isoforms at each 
polymorphic site in the absence of association between transcript isoforms and SNP 
alleles. The computer simulations were performed by constructing random replicates of 
the data under a null model of no association between SNP allele and mRNA isoform, but 
with the restriction that row and column sums for each matrix were conserved. The 
number of matrices in the simulated datasets with a zero cell were counted and used to 
estimate the expected number of matrices with a zero cell in the absence of an association 
between transcript isoforms and SNPs. Confidence intervals were determined and these 
included the values obtained from 95% of the replicates. We also constructed randomized 











column of the matrix was introduced in a randomly selected proportion of the matrices. 
Using these simulated datasets we estimated the proportion of affected matrices required 
to reproduce the observed number of matrices with a zero cell.  
 
Fisher's exact test, a non-parameteric test, was used to test the null hypothesis of no 
association between the transcript isoforms and the SNP alleles for individual matrices. 





ASAP (Modrek et al., 2001), is one of the many databases of alternatively spliced 
isoforms based on gene expression evidence from dbEST (Wheeler et al., 2007). To 
harness allele-specific splicing information in the ASAP database, our approach relies on 
SNPs and transcript isoforms that can be mapped to transcript sequences from the public 
databases. We created a database of 1295, 2X2 matrices from ESTs that can be mapped 
to SNPs and alternative mRNA isoform pairs. Figure 2 illustrates how the matrices were 
constructed using the RPNC4/RBM23 gene as an example. Matrices that have a column 
or row sum of 1 are forced to at least have a zero cell, which we cannot be certain to be 
caused by an allelic effect. Such matrices could simply be reflecting insufficient data. 
From this database of matrices, we observed 139 matrices that contained rows and 
columns each summing to at least two, thus representing at least two different mRNA 
isoforms and two different alleles. We considered these 139 matrices to have sufficient 
EST data to analyse allele-specificity, hence our analysis was based only on these 
matrices.  
 
4.3.2 Estimation of allele-specific splicing in human 
 
In the case of qualitative allele-specific isoforms, every matrix that is affected necessarily 











expected where an exonic SNP has a direct qualitative effect on splicing and each SNP 
allele is completely associated with exactly one transcript isoform. However, matrices 
with two zero cells are not always expected for exonic SNPs that actually cause 
qualitative allele-specific splicing. For example, one SNP allele may give rise to the wild 
type isoform while the newly acquired SNP allele causes the expression of a mixture of 
both alternate isoforms. A concrete example of a one zero cell matrix from qualitative 
allele-specific splicing is shown in Figure 2B. Among the observed matrices, 85 had a 
zero cell (i.e. one combination of SNP allele and mRNA isoform that did not occur) and 
were thus consistent with qualitative allele-specific splicing. In equivalent sets of 
randomized matrices, on average, 71 matrices had a zero element (Figure 3). Only four 
out of 1000 replicates had as many or more matrices with a zero cell as found in the 
observed data (i.e 85 matrices). There are 14 extra matrices in the observed data (85 -71 
matrices), with at least one zero cell is not likely to have resulted from random data with 
no relationship between SNP allele and transcript isoforms and instead indicates the 
presence of allele-specific isoforms in the data.  
 
The numbers of matrices (with 95% confidence individual confidence intervals), with a 
zero cell from 1000 simulated replicates are shown in Figure 4A. The horizontal line in 
Figure 4A shows the number of matrices with a zero cell in the observed data. If we 
consider qualitative allele-specific splicing as the only alternative to random association 
(ie quantitative allele-specificity not allowed), the proportion of allele-specific isoforms 
can be inferred from the intersection of the horizontal line with the simulated data points. 
This intersection, shows additional matrices with a zero cell in the observed data which 
correspond to the average number of matrices without a zero cell in the randomized 
datasets. Hence, we can deduce from Figure 4A that the proportion of allele-specific 
splicing most consistent with 14 additional matrices with a zero cell in the observed data 
is 21%. The lower (6%), and upper bound (36%), of our estimate were easily inferred 
















Figure 3: A histogram showing the proportion of matrices with a zero cell from 1000 randomized replicates of the 
dataset.The arrow indicates the number of matrices with a zero cell in the observed data 
 
Quantitative allele-specificity, can also increase the number of matrices with a zero cell 
in the data but it does so less efficiently than qualitative allele-specific splicing. We 
modelled the situation where a proportion of the matrices in the dataset showed a strong, 
but not exclusive, association between transcript isoform and nucleotide polymorphism 
and used simulation to estimate the expected number of matrices with a zero cell. The 
association between rows and columns for the affected matrices was such that, for an 
individual EST, the probability of it being isoform k given that it is SNP allele i was four 
times the probability of being isoform k given that it is SNP allele j. With this fourfold 
association, at least 14% of the isoforms in the dataset would need to be quantitative 
allele-specific in order to explain the observed number of matrices with a zero cell. The 
real data are likely to contain a mixture of qualitative and quantitative allele specific 
isoforms. Combinations of proportions of qualitative and quantitative allele-specific 
forms that would most likely result in the number of zeros in the observed data are shown 














Figure 4: Simulations of qualitative and quantitative allele-specific transcript isoforms. A) Average numbers of 
matrices with a zero cell from 1000 simulated replicates of the dataset in which a proportion of the simulated matrices 
are derived from qualitative allele-specific transcript isoforms. The horizontal line shows the number of matrices with a 
zero cell in the observed data. The shaded area shows the confidence interval and the dark line the proportion of 
qualitative allele-specific isoforms most consistent with the observed number of matrices with a zero cell. Error bars 
were derived from the simulation as described in the method section. B) Combinations of qualitative and quantitative 
allele-specific transcript isoforms that could explain the observed number of matrices with a zero cell in the data. The 
points on the graph show the proportions of qualitative (y-axis) and quantitative (x-axis) allele-specific isoforms in the 
simulations that result in approximately the same number of matrices with a zero as we have observed in the data. In 
this example the strength of the association between rows and columns of the simulated matrices was such that, for an 
individual EST, the probability of it being in column k given that it was in row i was a factor of four higher than the 












A significant weakness in our estimation of the proportion of alternatively spliced genes 
that are allele-specific results from restricting to a single transcript sequence per cDNA 
library. This greatly reduced our dataset and consequently the accuracy of our estimation. 
This restriction is imposed to prevent inflating our estimate of allele-specific splicing in 
human as a result of tissue-specific isoforms. For simplicity we have illustrated in Figure 
4 how tissue-specific splicing could be falsely detected as allele-specific splicing. Such 
associations can be highly significant if there are many ESTs of the gene in the two 
cDNA libraries in which it occurs. We therefore sampled a maximum of two ESTs per 
cDNA library (one for each allele of the SNP from heterozygous libraries and just one 
from homozygous libraries). 
 
 
Figure 5: Two different cDNA libraries created from different tissues and two homozygous individuals. An exon 
skipping event that occurs in a tissue-specific manner and which is not in any way allele-specific is used for illustration. 
If all transcripts from these two cDNA libraries are sampled, the resulting data matrices (bottom), indicate an 











4.3.3 Detecting individual examples of allele-specific splicing 
 
Given a 2X2 matrix that represents a set of transcripts that can be mapped to two 
alternative transcript isoforms and alternate SNP allele we could test for non-random 
associations between isoforms and SNPs using Fisher’s Exact Test. We restricted the 
tests to only those matrices that could achieve a maximal p-value of 0.001 based on their 
row and column totals, to reduce the correction for multiple testing. An example of a data 
matrix is shown in Figure 2 for the gene RNPC4/RBM23. The P-value for the association 
between the rows and columns of the matrix shown is 0.0002 (from a 2-tailed Fishers 
Exact Test). The highest statistical significance (p < 2 X10-8) of any matrix in the dataset 
was achieved for the association between this same isoform and another SNP 
(rs2295680) that was located closer to the alternatively spliced exon junction. Further 
lines of evidence seem to suggest that this gene does indeed have polymorphic splice 
variants that are found at sufficiently high frequency in the population to be detectable 
using different methods (Hull et al., 2007). Firstly the association remains highly 
significant after correction for multiple testing, and secondly we have detected the same 
exon 6 skipping using another independent method. We detected the same allele-specific 
splicing event using an integrated analysis of ESTs, microarrays and genomic data 
(Chapter 5). For most matrices there are insufficient data to establish allele-specificity 




We report the first comprehensive genome-wide estimation of the prevalence of allele-
specific splicing in human using an integrated analysis of ESTs, SNPs and alternatively 
spliced gene transcripts. We propose a lower bound of 6% for the proportion of 
alternatively spliced genes for which either qualitative allele-specific or quantitative 
allele-specific transcript isoforms are present in the dataset. Our estimate of the 
prevalence of allele-specific isoforms took account of just one alternative isoform per 
gene, while there are multiple potentially independent alternatively spliced junctions for 











genes from the alternative splicing databases for which at least one allele-specific isoform 
exists may be far higher than the lower bound presented here. Furthermore, this analysis 
is based on association between transcript isoforms from qualitative and quantitative 
allele-specific splicing and exonic SNPs. However, only qualitative allele-specific 
splicing will cause the strongest association. As a consequence, our estimate of the 
proportion of qualitative allele-specific transcript isoforms required to explain the number 
of observed matrices with a zero cell is likely to also contribute to our underestimation of 
the prevalence of allele-specific splicing. 
 
There are several caveats associated with EST data which are also likely to contribute to 
an underestimation of the prevalence of allele-specific splicing. ESTs are biased towards 
gene ends, approximately 80% of EST are sampled from the 3’ and 5’ untranslated gene 
regions. ESTs are also sparse for all but the most highly expressed genes. Some genes of 
great medical importance such as the BRCA1 gene that is known to be spliced in an 
allele-specific manner (Fackenthal et al., 2002) are not represented even by a single EST. 
This under-representation of genes in the EST data has also been highlighted by an 
investigation that quantified the number of chromosome 22 genes represented in the EST 
database. Only half of the genes on chromosome 22 are represented in EST databases (de 
Souza et al., 2000). Furthermore, even for genes that are represented by more than 100 
ESTs in dbEST such as the INII gene, both novel mRNA transcript isoforms and allele-
specific isoforms are still being discovered (Favre et al., 2003). These observations 
highlight the insufficiency of ESTs in capturing all genes and mRNA isoforms. 
 
The density of genetic variation in functionally relevant regulatory elements is expected 
and has been reported to be low, as a result of purifying selection (Fairbrother et al., 
2004). Despite this purifying selection, genetic polymorphisms are still amongst a 
multitude of factors that play a role in affecting splicing of mRNA in an individual 
specific manner (Hiller et al., 2006; Fairbrother et al., 2004). We propose that the allele-
specific splicing reported is likely to result from cis-acting allelic variations that affect the 
strength of splice signals or their regulatory elements. However, it is possible, that other 











spliced isoform could result directly from a polymorphic deletion spanning an entire 
exon. An example of such a variant was reported for the human growth hormone receptor 
(Pantel et al., 2000). In some instances, allele-specificity could also result from a 
polymorphism that determines whether nonsense mediated decay of one isoform occurs 
(Figure 1C). The SNP allele that leads to NMD could either be a nonsense mutation or a 
frame-shift mutation that results in an exonic premature termination codon. This could 
result in an under-representation of the transcript isoform derived from the allele 
containing the stop codon. In this case, both of the transcript isoforms are produced from 
each allele (true alternative splicing) but the likelihood of observing both isoforms would 
be reduced for the allele with the stop codon.  
 
Numerous studies have used public transcript data to investigate tissue-specific splicing 
(Xu et al., 2002; Minovitsky et al., 2005; Aouacheria et al., 2006). However, use of ESTs 
to estimate either tissue-specificity or allele-specificity is complicated by biases that exist 
during the generation of ESTs.  In some instances it is impossible to conclude from EST 
data alone whether significant associations between mRNA isoforms and SNP genotypes 
are due to true allele-specific splicing or could be attributed to tissue-specific splicing 
hence tissue-specific splicing can be falsely detected as allele-specific splicing (Figure 5) 
and vice versa. We restricted to one EST per isoform, per allele in any cDNA library to 
prevent inflating our allele-specific estimate as a result of tissue-specific isoforms. For 
example, the case illustrated in Figure 5 would have attained a p-value = 0.007937. After 
restricting to one EST per library the p-value is not significant. This EST sampling 
restriction was done at the expense of greatly reducing our power to detect genes that 
showed evidence of allele-specific splicing. Thus we have reanalysed the problem of 
predicting allele-specific isoform from EST data by developing a more robust maximum 
likelihood approach. This maximum likelihood approach explicitly models both regulated 
and allele-specific splicing with extra power from integrating information from all ESTs 
within a given cDNA library and across libraries (Chapter 5). 
 
Recombination events can reduce the signal in the data and could cause underestimation 











However, given the short distances between associated exonic SNPs and alternatively 
spliced isoforms in most cases, intervening recombination events are likely to be rare. It 
is possible that transcript isoform choice is also affected by an individual’s genotype at 
other unlinked loci, but our method is unable to detect this. Similarly, although EST 
sequences are known to be error-prone, random sequencing errors cannot introduce false 
positive associations between splice isoform and allele, though they are also a potential 
source of noise. 
 
The existence of polymorphic transcript isoforms within the human population is 
consistent with the recent discovery that exons found only in minor splice forms are often  
completely absent from the orthologous gene in human/rodent comparisons (Modrek et 
al., 2001). This is consistent with a high prevalence of allele-specificity among minor 
splice isoforms, because evolutionary changes in gene structure must originate as 
polymorphisms within species. An allele-specific isoform may become fixed in the 
population if it adds advantageous splice variants or, at least, does not severely 
compromise the function of the wild-type gene. It is also likely that most such variants 
persist because their allele-specific splicing events do not directly cause disease but only 
modulate severity of certain disease phenotypes caused by separate mutation (Buchner et 
al., 2003).   
 
 
We found a high prevalence of allele-specific splicing. Interestingly, no natural upper 
bound on the proportion of alternatively spliced genes that are affected by polymorphism 
emerges from our analysis and we argue that the contribution of allele-specific transcript 
isoforms should be stated as a caveat in future estimates of the prevalence of alternative 
splicing. Our results emphasize that true alternative splicing cannot be confirmed unless 
more than one transcript is observed from the same allele and also caution that any 














This chapter was perfomed in collaboration with Janet Kelso and Cathal Seoighe. I was 
responsible for the collection of data and most of the analysis. CS formulated the 



















Identification of Allele-specific mRNA transcripts in Human 




Accurate mRNA splicing depends on multiple regulatory signals encoded in the 
transcribed RNA sequence. Many examples of mutations within human splice regulatory 
regions that alter splicing qualitatively or quantitatively have been reported and allelic 
differences in mRNA splicing are likely to be a common and important source of 
phenotypic diversity at the molecular level, in addition to their contribution to genetic 
disease. However, because the effect of a mutation on the efficiency of mRNA splicing is 
often difficult to predict, many mutations that cause disease through an effect on splicing 
are likely to remain undiscovered. We have combined a genome-wide scan for sequence 
polymorphisms likely to affect mRNA splicing with evidence from publicly available 
Expressed Sequence Tag (EST) and exon array data. The genome-wide scan uses 
published tools and identified 30,977 Single Nucleotide Polymorphisms (SNPs) located 
within donor and acceptor splice sites, branch points and exon enhancer elements. For 
1,085 candidate splicing polymorphisms the difference in splicing between alternative 
alleles was corroborated by publicly available exon array data from 166 lymphoblastoid 
cell lines. We developed a novel probabilistic method to infer allele-specific splicing 
from EST data. The method makes use of SNPs and alternative mRNA isoforms mapped 
to EST sequences and models both regulated alternative splicing as well as allele-specific 
splicing. We report a set of genes showing evidence of allele-specific splicing from an 
integrated analysis of genomic polymorphisms, EST data and exon array data including 
several examples for which there is experimental evidence of polymorphisms affecting 
splicing in the literature. We also present a set of novel allele-specific splicing candidates 
and discuss the strengths and weaknesses of alternative technologies for inferring the 











that can be used to assess the possible effect on splicing of human polymorphisms in 
putative splice-regulatory sites. 
 
5.1 Introduction  
 
One of the key tasks of the post-genome era is to determine the functional implications of 
genomic variants.  The development of high throughput genotyping technologies and the 
use of these technologies in large-scale studies has enabled the identification of 
increasing numbers of human loci that are associated with common genetic disorders 
(e.g.(The Wellcome Trust Case Control Consortium, 2007)); however, the mechanisms 
through which genetic variants at many disease-associated loci affect disease 
susceptibility remain to be determined. Mutations or polymorphisms that affect mRNA 
splicing can have a profound effect on the function of the spliced product, but these 
effects are often difficult to predict from the primary g nomic sequence. The medical and 
biological significance of such variants is evident from the large and rapidly increasing 
volume of literature reporting examples of aberrant mRNA splicing associated with 
human cancers and genetic diseases (Faustino and Cooper, 2003; Wang and Cooper, 
2007). Indeed, point mutations leading to aberrant splicing are thought to be among the 
most important contributors to human genetic diseases (Lopez-Bigas et al., 2005).  
 
Sequence variants found on the pre-mRNA can affect a number of different, and in some 
cases imperfectly characterized, cis-acting sequences that control splicing. 
Polymorphisms that occur at the highly conserved donor and acceptor di-nucleotides are 
an obvious case in which we expect an effect on splicing (Krawczak et al., 1992) and 
these genomic variants, when they occur close to verified exon boundaries, tend be 
annotated in databases of sequence polymorphisms, such as dbSNP (Sherry et al., 2001). 
A much larger proportion of variants are likely to occur at sites where the effect on 
splicing is less obvious, for example at less conserved sites close to intron/exon 
boundaries, close to the intronic branch-point (Kralovicova et al., 2006b), or within 
intronic or exonic splicing enhancer or suppressor sequences (Cartegni et al., 2002). In 











aberrant splicing of a proportion or of all of the transcripts produced. However, if the 
gene is alternatively spliced to begin with, then sequence variants that affect sites that are 
involved in controlling isoform abundance may be affected, causing allelic differences in 
the regulation of alternative splicing, with potentially important biological consequences 
(Buchner et al., 2003). 
 
The contribution of heritable variation to the observed diversity of mRNA splice isoforms 
is well established (Nembaware et al., 2004; Hull et al., 2007; Kwan et al., 2007). Using 
the ASAP database of alternatively spliced mRNA isoforms (Modrek et al., 2001) and 
transcribed SNPs, we previously estimated that approximately 20% of alternatively 
spliced genes show evidence of allele-specific splicing either complete allele-specific 
splicing, in which one allele gives rise to one isoform and another results in the 
alternative form, or partial allele-specific splicing in which different alleles result in 
distinct relative isoform abundance (Nembaware et al., 2004) (see Chapter 2). Earlier 
large-scale studies of alternative and allele-specific splicing relied primarily on Expressed 
Sequence Tag (EST) sequences. More recently, both exon-junction and exon tiling arrays 
have been used for genome-wide studies of alternative splicing (Johnson et al., 2003; Pan 
et al., 2004; Pan et al., 2004). The Affymetrix GeneChip Human Exon 1.0 ST Array has 
probe-sets targeting approximately 1.4 million known and predicted exons. Alternatively 
spliced mRNA isoforms detected using the Affymetrix exon array in cell lines genotyped 
as part of the HapMap project (The International HapMap Consortium, 2005), has given 
rise to opportunities for high-throughput discovery of alleles that affect mRNA splicing 
(Kwan et al., 2007; Hull et al., 2007). Though exon arrays are arguably a superior 
technology, with better exon coverage than ESTs (Kwan et al., 2007), they are also 
affected by a range of caveats (Lee and Wang, 2005). Integration of results from ESTs 
and microarrays is likely to increase power to detect allele-specific splicing as both arrays 
and ESTs have different limitations and advantages for the analysis of alternatively 
spliced isoforms. 
 
Though for the present it remains a distant goal, a complete description of the effect of 











understanding human genetic diseases and phenotypes. One option for evaluating the 
potential effect of cis-acting mutations on splicing is to use ab initio prediction 
algorithms that make use of the availability of the complete genome sequence (Yeo and 
Burge, 2004; Cartegni et al., 2003). In several previous studies, computational tools have 
been effective in helping to shed light on the impact of a mutation on splicing (Buchner et 
al., 2003; Kralovicova et al., 2006a; Kralovicova et al., 2006b) and databases of 
mutations that may affect splicing have been made available (Conde et al., 2006; Li et al., 
2007). However, because of the difficulty of predicting all splice regulatory elements 
from genomic sequence and the even greater difficulty of determining accurately the 
effect of mutations in these regions on splicing, genomic analysis of SNPs likely to affect 
splicing needs to be complemented by expression data that provides information about 
the splice isoforms that are associated with the alternative alleles of a candidate SNP. 
 
We have performed a genome-wide scan for Single Nucleotide Polymorphisms (SNPs) 
likely to influence splicing efficiency in cis using publicly available tools (ESEfinder, 
(Cartegni et al., 2003), MaxEntScan (Yeo and Burge, 2004), and Branch Site Analyzer 
(Kol et al., 2005). We have tested predictions based on genomic sequences using publicly 
available EST and exon array data. We present a novel probabilistic method to infer 
allelic differences in mRNA splicing from EST data and used recently published 
Affymetrix exon array hybridisation data derived from 166 lymphoblastoid cell lines 
(Huang et al., 2007) for which genome-wide genotype data are available through the 
HapMap project (The International HapMap Consortium, 2005) to test for association 













5.2.1 Splice site strength prediction 
 
We downloaded known transcripts, chromosomal genomic data and SNP and exon tables 
from Ensembl version 36 (Birney et al., 2006), which is based on NCBI Genome build 
35. Genes and SNPs that mapped to multiple locations on the genome were discarded. 
Introns were inferred from the exon genomic coordinates obtained from Ensembl. SNP 
positions relative to the Ensembl exons and introns were identified via genomic 
coordinates. SNP positions relative to exon/intron junctions were also determined for 
isoforms obtained from the ASAPII database.  
 
Published tools for detecting splicing regulatory elements were either requested from 
authors or downloaded from their respective sites. We extracted 9 nucleotides from the 
donor splice sites and 23 nucleotides from the acceptor splice sites as required by the 
maximum entropy algorithm of Yeo and Burge, (2004). Scores for each pair of alternate 
alleles were then calculated (Yeo and Burge, 2004). We also identified an inflated 
frequency of SNPs at the G base of the canonical AG acceptor site which has been 
previously identified as a sequencing artifact (Platzer et al., 2007). We therefore restricted 
our analysis to validated SNPs using the information from dbSNP125 in the Ensembl 
database. 
 
The ESEfinder tool (Cartegni et al., 2003) is designed to predict four ESEs: SC35, ASF2, 
SRp55 and SRp40. ESEfinder uses a position specific weight matrices. An ESE is 
considered to have a pre-defined length, m, and a recommended minimum score S. For 
each SNP we extracted m -1 nucleotides up- and downstream of the SNP. We then 
calculated the ESE scores for each of the contiguous length m subsequences of this 
sequence. The highest score for each SNP allele was retained if at least one of the scores 
was above S and the other below S. Although some strong ESEs can influence splicing at 
a distance of several kilobases (Graveley et al., 1998), functional ESEs are most abundant 
in close proximity to splice junctions of internal exons (Fairbrother et al., 2004). We 











of internal exons. Branch point scores for pairs of alternate SNP alleles were computed 
using Perl scripts provided by Kol et al., (2005). 
 
5.2.2 Mapping exonic SNP alleles to splice variants 
 
We downloaded pre-computed EST and SNP genomic locations from the UCSC Genome 
Browser (Karolchik et al., 2003), which is based on NCBI genome assembly 36. ESTs 
and SNPs that mapped multiple times onto the genomic sequence and ESTs for which 
less than 90% of the sequence mapped to the genome were discarded. We used SNP and 
EST genomic coordinates to identify the SNP allele corresponding to each EST 
overlapping the SNP position. ASAPII (Kim et al., 2007), a database of alternatively 
spliced gene clusters, was downloaded on 9/11/2006. This data included gene and exon 
genomic locations based on NCBI genome assembly 35 as well as alternative mRNA 
isoforms (represented by conflicting exon junction pairs) mapped to ESTs.  
 
5.2.3 Models of regulated and allele-specific splicing 
 
For a given allele, A, of an alternatively spliced gene with alternative splice isoforms S1 
and S2, let x represent the proportion of isoform S1 produced from allele A in a cDNA 
library. We assume that x is constant for a given allele and library, but may vary across 
alleles and/or libraries. The purpose of the model is to determine, using data from several 
libraries (in which alternative transcript isoforms may be differentially regulated and have 
different relative expression levels), whether x shows significant variation across alleles. 
 
Consider cDNA library i with N transcripts from allele A, of which we observe ai ESTs 
that map to S1 and bi = N-ai ESTs that map to S2. Because ai is binomially distributed 
with binomial parameter x, we use the beta distribution (conjugate to the binomial) to 
describe the probability density of x. We share this distribution across all libraries but not 
necessarily across the two alleles. Thus the values of x for separate libraries are modeled 
as independent draws from the distribution f(x, αA, βA) for allele A and f(x, αB, βB) for 












The likelihood of the data from allele A observed in library i can now be expressed as 






ii βαβα (1) 
The likelihood of the data observed in all cDNA libraries is a product over terms such as 
this, and the α and β parameters can be estimated by optimizing the likelihood for the 
combined data set. 
 
An analytical solution to the integral of equation 1 exists, resulting in the following 
expression for the likelihood of the complete data for a pair of alternate isoforms and 
SNP alleles: 








βαβαβαβαβαβα ,,,|  (2)  
where ai, bi are the numbers of ESTs in cDNA library i that map to allele A and splice 
junctions S1 and S2 respectively and ci, di are the corresponding EST counts for allele B. 
The maximum likelihood parameter estimates were obtained by optimizing the likelihood 
using Powell’s method (Press et al., 1992). 
 
For the null model, we impose the restriction that αA = αB and βA = βB, such that both 
alleles are considered to be sampled from the same distribution (no allele-specific effect). 
To model allele-specific splicing (the alternative model), we allow αA ≠ αB and estimate 
separate beta distributions for the alternate alleles of a SNP (we keep the constraint βA = 
βB because we found that this model already has sufficient freedom to model the desired 
effect and adding another degree of freedom was unnecessary). If the null model can be 
rejected in favour of the alternative model (using the likelihood ratio test) we conclude 




We constructed 1000 random replicates of the EST data such that, for every SNP, the 
number of libraries derived from each genotype of the SNP was identical to the real data. 
Each library in the simulated data was assigned a genotype, with a probability 











was adjusted as each simulated library was assigned a genotype). For each library, the 
total numbers of ESTs derived from each isoform was constrained to be the same as in 
the real data. For heterozygous libraries ESTs were assigned to alternative SNP alleles 
with equal probability.  
5.2.5 Analysis of Affymetrix exon arrays 
 
We obtained whole genome exon data from the Gene Expression Omnibus (Barrett et al., 
2007), which were generated using the Affymetrix Human Exon 1.0ST array by Huang et 
al. (Huang et al., 2007). These data were generated from 166 lymphoblastoid cell lines 
for which genome-wide genotype data are available through the HapMap project (The 
International HapMap Consortium, 2005). SNPs that overlap with probes can affect 
binding affinities and potentially result in spurious identification of differential 
expression (Kwan et al., 2007). We therefore removed all probes that overlapped with
SNPs from dbSNP, from further analysis (Kwan et al., 2007).  
 
The exon array data was processed using the Affymetrix Power Tools. F r all probesets, 
we used the Plier Sketch algorithm to estimate expression level in each cell-line, and 
DABG was used to estimate detection above background probabilities (Affymetrix, 
2007).  For the meta-probeset (transcript) level expression we used only the high 
confidence (or ‘core’) probesets from the array to avoid inaccuracy caused by the 
inclusion of computationally predicted probesets (Kwan et al., 2007). For each probeset 
that mapped to a meta-probeset, the splicing index (SI) was calculated by dividing the 
probeset expression estimate by the estimate of the transcript-level expression in each cell 
line. The core meta-probeset expression estimate was used for non-core probesets that 
mapped to core as well as non-core meta-probesets. 
 
We used a robust linear model to test for an association for each srSNP, between the SI of 
all probes within 1kb of the probe and SNP genotype, treating HapMap population as a 
covariate. We used Holm correction (with significance level 0.05) to control the family-
wise error rate and to establish a high-confidence or conservative set of probes with 
allele-specific SI. A false detection rate correction (also with cut-off set to 0.05) was also 











inferences. All statistical analyses were performed using the R statistical computing 
environment (The R Project for Statistical Computing, ; Ihaka and Gentleman, 1996). 
 
Table 1: Summary of srSNPs with supporting evidence from EST and Exon array data. 
Cis element srSNPs EST evidence 




(Holm corrected α = 0.05) 
Donor 1970 47 84 20 
Acceptor 7248 156 217 22 
Branch 2689 41 75 13 
SC35 5910 44 257 26 
SF2 8992 82 387 44 








5.3.1 A genome-wide scan for polymorphisms in splice-regulatory 
regions 
 
We used published computational tools to identify 30,977 polymorphisms that occur 
within predicted or known splicing regulatory sequences (which we refer to as srSNPs), 
including donor sites, acceptor sites, branch points (BP) and exonic splice enhancer 
(ESE) elements. The number of SNPs occurring in putative ESEs is much higher than the 
number in the other cis elements (Table 1). This is likely to be due, at least in part, to the 
high false positive rate of ESE identification compared to the other splice regulatory 
elements that are identified using positional information, rather than by matching to 
sequence patterns alone. For each type of splice-regulatory element, publicly available 
tools were used to score the sequences associated with alternative SNP alleles (Methods). 
We used gene structure information from Ensembl (Birney et al., 2006) as well as from 
ASAPII (Kim et al., 2007), to identify srSNPs. This greatly increased our coverage, for 











17 in dual-specificity sites (Zhang et al., 2007)), 3,868 occurred within exon-intron or 
intron-exon boundaries common to both databases while 2,759 were unique to Ensembl 
and 2,574 were unique to ASAPII.  
 
5.3.2 A maximum likelihood method to identify allele-specific splicing 
using EST data 
 
We previously used linkage disequilibrium between SNPs mapped to EST sequences and 
alternative splice isoforms to identify allele-specific mRNA isoforms (Nembaware et al., 
2004). However, because alternative splicing can be regulated in a tissue-specific way 
and because multiple ESTs from the same gene can occur in a single cDNA library, we 
restricted our previous analysis to just one EST per cDNA library per alternative isoform 
pair. To make better use of the available data we have now developed a probabilistic 
model that can be applied to detect allele-specific splicing from SNPs mapped to EST 




Figure 1: Part of the genomic sequence of the OAS1 gene showing alternative acceptor site use at exon 7. The putative 
causative SNP (rs10774671), which occurs at the G site of the canonical acceptor dinucleotide, and an mSNP (rs2660), 
which was used to infer allele-specific splicing from EST data, are shown. Splice isoforms and mSNP alleles observed 
in three of a total of 27 cDNA libraries with ESTs that mapped to this region are also depicted. For each library the data 
are summarized in a two-by-two contingency table, with each EST cross-classified according to mRNA isoform and 











The possibility that the isoform is regulated in a tissue-specific way is modeled explicitly. 
For a given pair of mutually exclusive mRNA isoforms, the proportions of each isoform 
that occur across different cDNA libraries are modeled using a beta distribution. An 
allelic effect on splicing is inferred when a model that allows separate beta distributions 
for two alternative alleles of a SNP (which maps to both isoforms) provides a better fit to 
the data than a model with a single distribution for both alleles. We found 1,753 marker 
SNPs (i.e. SNPs in linkage disequilibrium with a splicing event, which we refer to as 
mSNPs), corresponding to 1,318 genes and 2,283 alternative splice junction pairs, for 
which the allele-specific mRNA splicing model provided a better fit to the data than the  
null model at the 5% significance level, using the likelihood ratio test. 
 
The distribution of the likelihood ratio test statistic is asympt tically chi-squared for large 
sample sizes under the null hypothesis. To test the validity of the test on the observed 
data, for which the number of data points per test was highly variable, we simulated data 
identical to the observed data in terms of the numbers of ESTs mapping to alternative 
alleles and splice isoforms but conforming to the null hypothesis of no association 
between mRNA isoform and allele. The cumulative distribution of the likelihood ratio 
statistic on this simulated data was consistently lower than the chi-squared distribution 
with one degree of freedom (data not shown), which suggests that the likelihood ratio test 
provides a conservative basis on which to reject the null hypothesis. The distribution of p-
values from the simulated data was also not uniform because of the sparseness of the data 
available for many of the mSNP and splice junctions that were tested. This complicates 
the application of standard false discovery rate methods to account for multiple testing. 
Instead we compared the observed and simulated distributions of the likelihood ratio test 
statistic, which allowed us to estimate the proportion of false discoveries at all levels of 
the test statistic (Figure 2). There were 91 cases of association between mSNPs and splice 
isoforms at the true positive rate cut-off of 0.8, shown on the graph (corresponding to 
approximately 73 true positives and 18 false positives). These came from 54 distinct 




















Figure 2: Analysis of simulated EST data. The number of true positives and the true positive rate (equal to one minus 
the false discovery rate) as a function of the likelihood ratio test statistic were estimated from 1000 randomizations of 
the matrices of counts of ESTs mapping to alternative SNP alleles and alternative splice isoforms. The solid line shows 
the number of true positives obtained when the true positive rate is 0.8 (i.e. at a false discovery rate of 0.2). 
 
5.3.3 Support for srSNPs and mSNPs from publicly-available exon 
array data 
 
Exon array data generated by Huang et al. (Huang et al., 2007) from 166 lymphoblastoid 
cell lines using the Affymetrix Exon 1.0ST were downloaded from the GEO database 
(Barrett et al., 2007), and processed as described in Methods. The splicing index (SI; 
(Clark et al., 2002)) was calculated for each probeset, by dividing the probeset-level 











Probesets analysed included high-confidence core probesets as well as probesets 
corresponding to predicted exons. The transcript-level expression estimates were inferred 
using core probesets only, to avoid inaccuracy caused by including spurious probesets in 
the transcript-level expression estimate (Kwan et al., 2007). Genome-wide genotype data 
for almost four million SNPs were available for the same cell lines through the HapMap 
project (The International HapMap Consortium, 2005). For each putative srSNP and 
mSNP for which genotype data were available we tested for an effect of genotype on SI 
for each probeset in the region of the mSNP or srSNP, treating the HapMap population 
from which the sample was derived (Yoruban or Caucasian) as a covariate, and using a 
robust linear model and robust analysis of variance (ANOVA), implemented in the 
Insightful Robust Library of the R package (The R Project for Statistical Computing, 
Ihaka and Gentleman, 1996). In the case of srSNPs, because it is often difficult to predict 
the impact of the SNP on splicing, all probesets within 1kb of the SNP were tested. For 
the mSNPs we tested only probesets that fell within the genomic boundaries defined by 
the alternative exon junctions of the putatively allele-specific splice isoforms. Similarly, 
to determine whether an srSNP was supported by EST data, we tested whether the srSNP 
fell within the genomic region defined by the alternative exon junctions (including 3bp of 
the corresponding exons in the case of putative exonic splice donor and acceptor 
mutations). Examples of srSNPs for which there was strong evidence of an allelic effect 
on splicing from the exon array data (Holm-corrected p-value < 0.05) are shown in 
Figures 3 and 4. Similar diagrams are available for a total of 1,083 putative srSNPs for 















Figure 3: Support for allele-specific acceptor site use in the OAS1 gene. A) Genomic sequence of the OAS1 gene 
showing the alternatively spliced exons. The boxed section is magnified and drawn to scale in the next panel. B) 
Relationship between the genotypes of the SNP and the splicing indices of nearby probesets, illustrating that there is 
likely to be a complex pattern of allele-specific splicing in this gene. Probesets in red are significantly associated with 
the SNP genotype. The p-values for the association of these probesets to SNP genotypes are also included. Unfilled 
rectangles represent probesets tha were not tested for association with the genotype because they were not detected 
above background in a sufficient number of the cell lines or were too distnat from the SNP. C) Histograms showing the 
splicing index distribution as a function of the genotype of a SNP, rs10774671, at the G nucleotide of the canonical 
splice acceptor site. D) Association plot illustrating that rs10774671 is more strongly associated with a probeset 
















Figure 4: Support for allele-specific exon-skipping in the GLO1 gene. A) Genomic sequence of the GLO1 gene 
showing the alternatively spliced exons. B) Illustration of the relationship between the genotypes of this SNP and 
splicing indices of nearby probesets, using the same conventions as in Figure 3. C) Histograms showing the splicing 
index distribution as a function of the genotype of a SNP, rs2736654, predicted to affect an exonic splice enhancer site. 
D) Association plot illustrating that rs2736654 is marginally more strongly associated with a probeset spanning exon 4 
















Table 2: A subset of the previously reported allele-specific splice isoforms detected in this study 




srSNP Cis-element References 
CD45 Exon 4 rs12129883 
(0.020551) 
--- --- ESS (Jacobsen et al., 
2002) 
COL5A1 Exon 65 rs13946 
(0.046) 
--- --- Acceptor site (Wenstrup et al., 
1996) 
ETV4 Exon 3 rs3765174 
(0.014) 
--- --- NAGNAG 
acceptor 
(Hiller et al., 
2006) 
GABRR1 Exon 2 rs12200969 
(0.034) 
--- rs4590242 NAGNAG 
acceptor 










YES --- Exonic splicing 
silencer element 
in exon 2 




Exon 12 --- YES rs688 SF2 (Zhu et al., 
2007) 




--- --- Acceptor site (Ligtenberg et 
al., 1991) 
OAS1 Exon 7 rs2660 
(0.00063) 
YES rs10774671 Acceptor (Bonnevie-
Nielsen et al., 
2005) 
PMM2 Exon 5 rs2072688 
(0.0027) 
--- --- ESE (Vuillaumier-
















--- --- --- (McManus et 
al., 1996) 
* Hull et al. (2007) did not report that the SNP, rs2295982, disrupts an ESE 
 
Among the classes of splicing regulatory regions analysed, SNPs that occurred in donor 
sites were slightly more likely to be confirmed by EST and/or exon array data (Table 1). 
In addition to the srSNPs for which there is supporting evidence from EST and/or exon 
array data a further 51 mSNPs were supported by exon array data, but no candidate 
srSNP was identified that could explain the allelic difference in splicing. Some of these 
may be false positive mSNPs but for the remainder, the causative SNP may be in an 
intronic splicing element (intronic splicing elements were not included in the genome-











possibility also exists that some of the identified putative allele-specific isoforms are 
caused by mutations located within trans regulators of splicing and that association with 
nearby polymorphisms is a result of population stratification rather than a direct cis-
acting effect.  
 
5.3.4 Cross-validation of EST and exon array results 
 
15 out of the 54 distinct alternate exon junction pairs with evidence of allele specific 
splicing from the EST data using a false detection cut-off of 0.2 (above), could be tested 
for allele-specific splicing using the exon array data. In order to be tested, the 15 mSNPs 
had to be among the SNPs genotyped in the HapMap populations, a probe or probes had 
to occur between the genomic coordinates spanned by the alternative exon junction pair 
and the probe had to be detectable above background in at least some of the 
lymphoblastoid cell lines. Of these 15, 9 (60%) had at least one probe between the 
genomic coordinates of the junction pair for which the SI was significantly associated 
with the genotype of the mSNP (p < 0.05, with Bonferroni correction in the case where 
multiple probes were tested for association with a single mSNP). By comparison, there 
were 29 (23%) associations from 124 exon junctions that could be tested from a random 
set of 10,000 alternatively spliced exon junction pairs from ASAPII and nearby exonic 
SNPs that showed no association with the mRNA isoform. The proportion of allele-
specific splicing candidat s from the EST data that could be confirmed using the exon 
array data was significantly higher than for alternatively spliced exon junctions with no 
evidence of allele-specificity from ESTs (p = 0.005 using Fisher’s Exact Test). This 
overlap of allele-specific splicing candidates identified by very different technologies, 
provides cross-validation for the candidates identified using the two approaches. 
5.3.5 Splicing index association plots 
 
A significant association between the SI of a probeset and an srSNP is insufficient to 
infer a causal relationship between the srSNP and variation in SI. It is possible that the 
putative srSNP is not causally related to the observed difference in splicing and, instead, 











splicing (because of the imperfect understanding of splicing regulation). We can begin to 
investigate this possibility by testing for an association between the SI and genotype for 
all of the other nearby SNPs for which genotype data are available for the lymphoblastoid 
cell lines. For each srSNP we tested for an association between SI and genotype for all 
genotyped SNPs within 10kb of the srSNP. On average there were 25 such SNPs per 
srSNP.  For the majority (61.8%) of the srSNPs strongly supported by the exon array 
data, the predicted srSNP showed the most significant or joint most significant 
association between SI and genotype for at least one of the probesets tested. For the 
remainder, an alternative SNP, not necessarily predicted to affect splicing, showed a more 
strongly significant association. The mechanisms through which these alternative SNPs 
may affect splicing require further investigation. Examples of the association plots are 
shown in Figures 3 and 4. Similar association plots for all of the srSNPs supported by the 
lymphoblastoid exon array data are available from our website.  
 
5.3.6 Analysis of allele-specific mRNA splicing candidates 
 
For several of the examples of allele-specific splicing that we identified we were able to 
find published research articles confirming the same event (Table 2). The mSNP rs2660 
(p = 0.0006; Figure 1), which we detected in the 2',5'-oligoadenylate synthetase 1 (OAS1) 
gene, for example, has been shown experimentally to be in strong linkage disequilibrium 
with the srSNP, rs10774671, which occurs at the G of a canonical acceptor site 
(Bonnevie-Nielsen et al., 2005). Disruption of the canonical acceptor site in intron 6 of 
the OAS1 gene promotes the use of two cryptic acceptor sites. Using the EST data we 
detected one of the cryptic acceptor sites, located 98 bps from the wild type acceptor site 
(Figure 1). This event was also detectable using the lymphoblastoid exon array data 
(Figure 3). 
 
There are also many cases of previously unpublished splicing polymorphisms among our 
results, some of which are likely to be functionally and medically important. For 
example, the lymphoblastoid exon array data provide strong evidence (robust Anova F 











GLO1 gene, encoding an enzyme (glyoxalase I) that has been reported to show lower 
activity in the brains of individuals affected by autism compared to control individuals 
(Junaid et al., 2004) and the genotype of a SNP in the same exon (C419A or rs2736654; 
Figure 4). Reduction in enzyme activity has been attributed to the direct effect of this 
non-synonymous SNP on the amino acid sequence of the protein. The ancestral A allele 
has been reported to be significantly associated with autism (Junaid et al., 2004) and 
certain types of panic disorders (Politi et al., 2006). A larger scale study, however, has 
questioned the association with autism, but has found that the A allele may have a 
protective effect in the siblings of individuals with autism (Sacco et al., 2007). This non-
synonymous SNP occurs in a predicted exon splice enhancer site (the genomic scan for 
srSNPs predicts that this site acts as an ESE for both SF2 and SRp55 and the A and C 
alleles have scores 0.44 and 2.96, respectively, for SF2 and 1.39 and 3.53, respectively 
for SRp55). EST evidence from ASAPII suggests that two exons are skipped (Kim et al., 
2007). Skipping of these exons is likely to have a much greater impact on the protein 
function than the replacement of Alanine by Glutamine at a single site within one of the 
exons. While the role of GLO1 in neurological disorders remains controversial 
(Thornalley, 2006), Sacco et al. (Sacco et al., 2007), highlight the need for further 
investigation of the functional impact of the C419A. Our results suggest that the 
polymorphism is very likely to impact on splicing. This could have a significant impact 




Large-scale discovery of genomic variants that affect splicing has the capacity to 
accelerate the association of diseases to causative genomic variants. However, because it 
is difficult and in many cases, currently not possible to determine the effect of a genomic 
variant on splicing or on the regulation of alternative splice isoforms from genomic 
sequence data alone, this remains a challenging task and requires the integration of 
information from different data types. At present, no single source of data can provide 
information about all forms of splice variants and each source of data has advantages as 











represents an extremely extensive dataset on isoform abundance in human 
lymphoblastoid cell lines that can be correlated with the genotype of the cell line. 
However, this data provides no information on transcripts that are not expressed in 
lymphoblastoids, or on splicing mutations that affect relative isoform abundance in only a 
subset of expression contexts. Furthermore, depending on the exact location of probesets 
in a given gene, many of the transcript isoforms that occur, particularly those that affect 
donor or acceptor site but do not cause exon skipping or inclusion, are undetectable using 
exon arrays. When alternative isoforms are distinguishable using the exon arrays, they 
still provide little information on the nature of the isoforms, and this may need to be 
inferred either by integrating information from other sources or experimentally. 
 
EST sequences provide information on the structure of alternative isoforms and include 
data from different gene expression contexts, but this information is highly biased 
towards ends of genes and is sparse, for all but the most highly expressed genes. The 
simulations provide ample evidence for frequent allele-specific splicing but also illustrate 
that there is not enough data to confirm most cases, especially when the effect of a very 
large number of statistical tests is considered. There were several published examples in 
the current study of genes known to be spliced in an allele-specific manner, but for which 
the allele-specific splicing model fits the data no better than the null model. EST data 
could have a low representation of allele-specific isoform as these are most likely to be 
minor isoforms, which are generally characterized by low expression levels.  However, 
although most cases of allele-specific splicing will not be detectable using EST sequences 
alone, ESTs can often be used to elucidate the nature of the allele-specific splicing events 
detected because ESTs provide information on the actual transcripts that occur.  
 
GLO1 provides an example of a gene with a mutation that is likely to affect splicing, but 
although there was good coverage of this gene in the EST databases, the allele-specific 
splicing event was not detectable from the EST data. Because the putative causal SNP is 
on the skipped exon it is only observed when the constitutive isoform occurs and 
therefore cannot be tested for association with the skipping event using the EST data. 











junction 334716 in ASAPII. There are also several cases of known splicing 
polymorphisms that could be detected from ESTs but not from the exon array data (Table 
2). The gamma-aminobutyric acid (GABA) receptor, rho 1, gene (GABRR1), for 
example, was previously shown to have a SNP (rs4590242), located in the acceptor site 
that promotes use of an alternate NAGNAG acceptor (Hiller et al., 2006). We detected 
this srSNP in the genomic data and EST data provided evidence of its effect on splicing 
with an mSNP rs12200969, (p-value=0.033921). However, due to the lack of a probe that 
coincides exactly with the end of the exon, the exon arrays were unable to detect this 
subtle alternative splicing event.  
 
The probability of linkage disequilibrium of an srSNP and mSNP decreases with the 
distance that separates them. This limitation is highlighted by the failure to associate 
several transcribed SNPs (rs3093906, rs3093905, rs3093921, rs3093925, rs3093926, 
rs3093927), located >5000bp away from a putative allele-specific splicing event in the 
Ribonuclease P RNA component H1 gene (PARP-2). The ASAPII database contains the 
two alternate donor sites at this junction that are 39bp apart and are supported by a total 
of 28 expressed transcripts, and two PARP-2 protein isoforms differing by 13 amino 
acids have been deposited in the SWISSPROT database (Boeckmann et al., 2003). We 
detected an srSNP (rs2297616) located at position 4 of the corresponding splice donor 
site and the exon-array data provide strong evidence for an association between the 
splicing index of a probeset that overlaps the 39bp region between the alternative donor 
sites and the genotype of this SNP ( p-value = 2.00 X 10-57).  
 
In previous work we used a heuristic method (see Chapter 4) to find associations between 
SNPs mapped to ESTs and alternatively spliced isoforms in order to detect candidate 
allele-specific isoforms and to quantify the proportion of alternatively spliced genes that 
are spliced allele-specifically.  However, such associations can also occur because of 
normal regulation of alternative splicing. For example, consider an alternatively spliced 
gene for which ESTs occur in just two of the cDNA libraries in dbEST. Assuming that 
these libraries were constructed from the tissues of single individuals, it is possible that 
these individuals have different genotypes for an exonic SNP in the gene. If the 











cDNA libraries are derived from different tissues then this could result in an association 
between the alleles of the SNP and the mRNA isoforms. This association can be highly 
significant if there are many ESTs of the gene in the two cDNA libraries in which it 
occurs. To circumvent this problem in our previous work, we took a maximum of two 
ESTs per cDNA library (one for each allele of the SNP from heterozygous libraries and 
just one from homozygous libraries). This caused a substantial loss of data and reduction 
in power to detect and quantify allele-specific mRNA splicing. In the present work we 
explicitly model the regulation of alternative splicing and make much better use of the 
available data.   
 
These results and previous reports (Nembaware et al., 2004; Kwan et al., 2007) suggest 
that polymorphisms that affect splicing are common. This has important implications, not 
only for discovering the molecular bases of genetic diseases, but also for the study of 
alternative splicing. A gene cannot be confirmed to be alternatively spliced unless 
multiple isoforms are observed from the same allele. Until then the possibility remains 
that the alternative isoforms observed are polymorphic variants rather than alternatively 
spliced. Although we have found ample evidence for allelic differences in splicing, 
isoforms that result entirely from sequence variants might be less common. In the set of 
examples we report here, there is a relatively small proportion of cases in which the data 
suggest that the SI might be zero for some variants. Allele-specific splicing may be 
particularly important in the context of investigations of the regulation of alternative 
splicing (Sugnet et al., 2006; Xu et al., 2002). Such investigations should ensure that 
multiple samples from the same tissue source are not treated as independent.  
 
Regulation of splicing is incompletely characterized and additional cis elements that 
regulate splicing are still being discovered (Yeo et al., 2007). A limitation of the current 
study is that the srSNP candidates are restricted to a subset of well characterized is-
acting splice regulatory elements (donor and acceptor sites, polypyrimidine tract, branch 
points and some exonic splicing elements). The phosphomannomutase 2 gene (PMM2), 
for example, which has allele-specific skipping of exon 5 due to a SNP that disrupts an 
ESE composed of (GAR)n repeats (Vuillaumier-Barrot et al., 1999), where R is a purine, 











because the disrupted ESE is not detected by ESEfinder. Polymorphisms not found in cis-
regulatory regions can also result in apparent allele-specific splicing if they introduce 
premature termination codons (PTCs) (Savas et al., 2006) and cause differential 
nonsense-mediated decay of alternative alleles. Such SNPs are not included in our srSNP 
database. We have also restricted our analysis to single nucleotide polymorphisms but 
allele-specific splicing could be due in many cases to other types of polymorphisms such 
as insertions and deletions (Romano et al., 2002). 
 
In the majority of the examples of allele-specific splicing we have detected, the 
difference in splicing is quantitative rather than qualitative. This can occur for a gene that 
is alternatively spliced, but for which a polymorphism exists that affects the proportions 
of alternative isoforms produced. In some cases, particularly for common 
polymorphisms, the size of the effect on SI can be relatively small, but still highly 
significant because of the relatively large number of individuals in each genotype group. 
In other cases, e.g the alternative isoforms of the OAS1 gene shown in Figure 3, the SI 
associated with one genotype may be much greater than for the other genotypes. In 
general, the size of an effect on SI sufficient for an effect on phenotype is likely to vary 
substantially from transcript to transcript. Consistent with what has been observed 
previously for cis-acting polymorphisms with a quantitative effect on splicing (Buchner 
et al., 2003), for the majority of the probesets for which SI was significantly associated 
with SNP genotype, the SI value of the heterozygote was intermediate to the SI of the two 
homozygotes. In 888 (77%) of 1,157 associations for which heterozygote and both 
homozygote cell-lines for the SNP were available, the SI of the heterozygote had an 
intermediate value. For stronger associations (that remained significant using a family-
wise error rate of 0.05), this figure was 242 (96%) from a total of 253.  
 
Using the expression quantitative trait loci (eQTLs) (Morley et al., 2004), as an analogy, 
loci that affect splicing might be termed splicing quantitative trait loci (sQTLs). In this 
study we have attempted to identify only cis-acting sQTLs. Trans-acting sQTLs are also 
likely to exist, particularly at genes that are involved in regulating alternative splicing. 











eQTLs, because of the relatively more complex regulation of transcription initiation 
compared to splicing. We have taken a candidate SNP approach to detecting splicing 
polymorphisms. With the availability of whole-genome exon array data it is also possible 
to adopt a less directed approach analogous to methods that have been used previously to 
detect expression quantitative trait loci (Morley et al., 2004). Each probeset could be 
tested for association with every SNP that overlaps the transcripts to which it belongs. 
However, because of the multiplicity of probesets per gene this would result in a very 
large number of tests and would be likely to yield a much larger set of candidates, but 
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Distinct inbred mouse strains exhibit a wide range of heritable and naturally occurring 
phenotypic differences; however, the molecular and functional basis of such variation is 
largely unknown. Numerous studies have reported detailed examples of strain-specific 
splicing with prominent consequences for gene function. Increased knowledge of strain-
specific splicing promises to be of great value in facilitating the use of mouse as a model 
for human disease in biomedical research. However, to-date, no genome-wide analysis 
has been performed, mainly due to the scarcity of genome-wide expression and genomic 
sequence data for most mouse strains with the exception of the reference strain, 
C57BL/6J.  Hence our analysis explores strain-specific splicing of C57BL/6J and related 
strains in comparisons to all other unrelated mouse strains that have publicly available 
transcript data. From our exploratory study, we estimate that differences in splicing 
between the C57BL/6J and related strain compared to unrelated strains occurs in about 
10% of alternatively spliced isoforms in the ASAPII database. Furthermore, we scanned 
for associations between the strain category from which the transcript is derived, and the 





















6.1 Introduction  
 
Since the early, 1900’s, over 100 inbred mouse strains with specific characteristics have 
been designed and propagated for use as animal models for human diseases (Beck et al., 
2000; Wade and Daly, 2005). Unlike the more recent strategy of developing new strains 
by directly tinkering with genetic material through sequence manipulation and induced 
mutations, previously, mouse breeders relied heavily on random heritable mutations that 
could be fixed in mouse colonies (Beck et al., 2000). Most of the commonly used mouse 
strains were established through phenotype-driven breeding and selection which took 
place well before the field of genetics was fully developed (Wade and Daly, 2005). Such 
heritable phenotypes are encoded by genetic variation in the ge omes of inbred mouse 
strains (Wade and Daly, 2005).  
 
The main source of these genetic variations is the different historic protocols that 
combined breeding and selection of a small but diverse group of ancestral Mus musculus 
species (Beck et al., 2000). A secondary cause of genetic variability in inbred mouse 
strains are spontaneous mutations that occurred in ancestral strains. The current challenge 
is to now discover the genetically c ntrolled molecular processes that are likely to 
mediate phenotypic differences which include differences in mRNA splicing.  
 
Numerous studies have revealed that genetically distinct mouse strains can have mRNAs 
with unique sets of exons (qualitative strain-specific splicing), or can differ in the rate of 
inclusion of specific exons in the mature mRNA (quantitative strain-specific splicing) 
(Buchner et al., 2003; Dolney et al., 2001; Sandilands et al., 2004). The effect of mouse 
strain-specific mRNA splicing on the mouse phenotype can be striking due to the 
potential of splicing polymorphisms to drastically alter gene functions. For example 
strain-specific isoforms of the K-opioid gene responsible for catalyzing alcohol has been 
implicated as the underlying cause of alcohol preference or avoidance in mice (Dolney et 
al., 2001). The DBA/2J mouse strain (alcohol avoiding) expresses an additional K-opioid 
receptor mRNA isoform in comparison to the alcohol preferring strains C57BL/6J and 












Quantitative strain-specific splicing has also been reported to contribute to mouse 
phenotypic variability as genetic modifiers of disease. The expression of strain-specific 
isoforms of the zinc finger protein gene (SCMN1) in the C57BL/6J strain and the C3H 
strain is the underlying cause of  variation in disease susceptibility in the B6 SNC8a medJ 
and C3H SNC8a medJ mutants (Buchner et al., 2003). Considering the potential impact of 
strain-specific mRNA splicing on phenotypic variability in mouse, disregarding strain-
specific mRNA isoforms would be a serious oversight.  
 
Important features of inbred mouse strains that make them ideal for biomedical research 
is their isogenicity (genetic identity) and the fact that each individual mouse is 
characterized by genome-wide homozygosity, which is achieved after at least 20 
consecutive generations of sibling mating (Beck et al., 2000). These characteristics make 
it easier to compare experimental results from geographically separated labs working on 
the same inbred strains. With the recent influx of transcripts from a wide range of inbred 
strains, collating publicly available mouse data offers an accelerated means of studying 
strain-specific splicing.  
 
To our knowledge no attempt has been made to perform a genome-wide study of the 
prevalence of strain-specific mRNA isoforms. A preliminary study of the transcripts in 
EMBL highlighted that transcripts are biased towards the mouse reference genome, 
C57BL/6J, with ESTs sparsely distributed across approximately 30 mice strains as shown 
in Figure 1. Given the biased distribution of transcript data towards the C57BL/6J, and 
the unclear relationships that exist among mouse inbred strains, the process of 
categorizing the data according to strains required the implementation of a transcript 
partitioning algorithm. We developed a method that exploits EST-derived SNP alleles to 
partition clone-libraries into two virtual strains; the B6 and the nonB6 strains. The B6 
constitutes the C57BL/6J and its related strains some of which are shown in Figure 2, 
while all the other inbred strains, not related to the C57BL/6J, fall under the nonB6 strain. 
We estimated the prevalence of B6 specific splicing, using transcript data that was used 
to support alternative splicing events in the ASAPII database (Kim et al., 2007). Our 











related mice (from the same or similar strains) and this provides an alternative approach 
for the detection of splicing variants that does not require expressed genetic markers in 
linkage disequilibrium with the splicing polymorphism (the method used for the human 
studies in Chapter 3 and 4). We also attempted to detect genes that are spliced in a strain-
specific manner by testing for associations between strain category (B6 and nonB6) from 
which the transcript is derived and the alternatively spliced isoforms from the ASAPII 
database (Kim et al., 2007).   
 
Figure 1: Pie-chart of the distribution of EST sequences according to cDNA library strain annotations. 




Figure 2: C57BL/6 and related strains (B6). One of the most widely used inbred strains is C57BL/6. Charles Little, an 
undergraduate student studying under Castle at Harvard University, obtained the ancestor of the C57Bl/6J from A.E.C 
Lathrop, a retired school teacher who was a mouse fancier.  Part of the genealogical history of the B6 strains is shown 
above highlighting that this strain has contributed to other sub-strains after crossings with other inbred strains such as 












6.2 Data and methods 
6.2.1 A database of SNPs mapped to ESTs 
 
We downloaded the UCSC mouse genome tracks (mm7) which are based on the NCBI 
genome assembly 36 (Karolchik et al., 2003) in August 2007. Mouse transcripts from the 
mouse transcript division of EMBL release 93 were downloaded from the European 
Bioinformatics Institute (www.ebi.ac.uk). All mouse transcripts together with their 
associated cDNA libraries and strain annotations were extracted from the EMBL flat 
files. The SNP to EST mapping procedure performed on human data (described in detail 
in Chapter 2), was applied to the mouse data and a similar MySQL database created. 
  
6.2.2 cDNA library classification 
 
cDNA libraries annotated as C57BL/6J or 57Bl/6J were used to compile a dataset of 
SNP alleles for what we termed the reference C57BL/6J dataset (ref-B6). Mouse inbred 
strains are expected to be homozygous at all loci and hence only one SNP allele is 
expected for each SNP location across the whole mouse genome. However, practically 
this is not possible due to sequencing errors and also due to at least the 5% heterogosity 
which exists in some inbred strains. We found a significant number of heterozygous 
SNPs in the ref-B6 SNP allele dataset. We assigned the SNP alleles to ref-B6 strain by 
calculating the most prevalent SNP allele. The most prevalent SNP allele for each 
individual cDNA library, that had transcripts in the SNP to EST dataset were also 
computed.  Based on the percentage of identical alleles between each cDNA library to the 
ref-B6 SNP allele dataset, we could classify libraries into three different categories, B6, 
















Mouse data from the ASAPII database was downloaded in August 2007. ASAPII 
provides alternatively spliced isoforms as pairs of mutually exclusive introns. The 
supporting transcript data used in the detection of alternatively spliced isoforms is also 
available in the ASAPII database. Transcript data that supported alternatively spliced 
isoforms and which could also be profiled either as B6/nonB6 strains as described in the 
previous section were used to create 2X2 contingency matrices for each alternatively 
spliced junction pair (Figure 3). A total of 32455 matrices were created, but only 3987 
matrices had row and column sums greater than 1 and were thus informative enough for 
further analysis (Chapter 4). 
 
We sampled one EST per library for each splice junction for the same reasons discussed  
previously in Chapter 4.  In the ASAPII database (Kim et al., 2007), a single alternatively 
spliced isoform can be represented by more than one pair of splice junctions. We 





In the case of qualitative B6-specific mRNA isoforms, every matrix affected necessarily 
has at least one zero cell in the nonB6 row. Figure 3 shows a matrix with a zero entry, 
using the SCNM1 gene which has a published strain-specific exon 6 skipping event 
(Buchner et al., 2003). We constructed 1000 randomized matrices of the observed data 
under the constraint that the rows and columns sums be preserved. For each replicate 
dataset, the number of matrices with at least one zero cell in the nonB6 row were 
counted. This is analogous to the method that we used to estimate the proportion of 
















Figure 3: A) The SCNM1 has been reported to be spliced in a strain-specific manner.  The C to T mutation that 
occurred in the B6 strain has been predicted to disrupt an ESE causing exon 6 skipping in the B6 mouse strains. B) The 
matrix constructed for the SCNM1 strain-specific splicing event using the profiled ESTs data that could be mapped to 
the ASAPII transcripts.  
      
We also constructed 1000 randomized replicates of the observed matrices such that a 
predefined proportion of the simulated matrices were forced to have at least one zero cell 
in the nonB6 row. For each of the replicate dataset, the number of matrices with at least 
one zero cell in the nonB6 row were then counted. 
 
6.2.5 Detection of individual cases of strain-specific splicing  
 
Given the large number of individual matrices being studied means that we expect several 
false positives purely by chance only. We therefore corrected for multiple testing using 















6.3.1 A map of SNPs mapped to ESTs  
 
A total of 740 cDNA libraries with 4,653,859 ESTs were extracted from the EMBL data 
files. However, only 667 cDNA libraries had at least one EST that mapped 
unambiguously to the genome and with a SNP located within its genomic boundaries. 
 
6.3.2 Classification of cDNA libraries as C57BL/6 or non C57BL/6  
 
To investigate strain-specific splicing in mouse using publicly available transcript data, 
classification of the cDNA libraries according to the strains they originated from is 
mandatory. Mouse has a well defined strain nomenclature system (www.jax.org), 
however there still exists a lack of uniformity in the strain labeling of cDNA libraries 
deposited in the public databases. For example there are numerous variations in the 
manner in which C57BL/6J cDNA strain libraries have been deposited; C57BL6J or 
C57Bl/6J or C57BL6J etc. Mis-breeding, genetic contaminations and strain mix-ups can 
occur, so animals from the same inbred strains from separate labs may no longer be 
isogenic. Furthermore, there is a large amount of overlap in mouse genealogical trees 
which intersect at several locations with unknown sequence contributions and genomic 
exchange (Wade and Daly, 2005). Therefore, relying on strain names alone to profile and 
partition transcript data is unreliable.  
 
Improvements in rapid genome-wide SNP genotyping methods has seen recent efforts to 
untangle mouse inbred strain relationships increasingly focusing on investigating 
relationships between inbred mouse strains using strain-specific allelic distribution of 
SNPs (Petkov et al., 2004a; Petkov et al., 2004b).  Petkov et al., (2004a) established a 
SNP-based method to profile inbred mouse using 235 SNPs in 48 mouse strains. A follow 
up study by the same group, using a set of 1639 SNPs effectively investigated mouse 
strain relations for a much bigger group of 102 mouse strains (Petkov et al., 2004b). The 
usefulness of the SNP profiling methods was shown by the ability of the study to verify 











trees for the mouse strains tested (Petkov et al., 2004b).  After a preliminary analysis of 
sequence data and noting the sparsity of data for most strains (Figure 1), we performed 
our analysis on strain-specific splicing in the B6 strain in comparison to all the nonB6 
strains. We then developed a SNP profiling method to classify libraries as B6 or nonB6 
using publicly available SNP and transcript data as summarized in the flow diagram in 
Figure 5. Of the 661 cDNA libraries that had at a least one polymorphic EST, only 409 
cDNA libraries had at least 30 SNPs and thus were informative enough for to use in the 
classification of cDNA libraries. We have categorized 348 cDNA libraries either as B6 or 
nonB6  and the remaining libraries we failed to categorise with certainty. An additional 
advantage to this approach is that even cDNA libraries that were not annotated according 
to the strain in the EMBL transcript data could be profiled using our method. 
 
Reliability of the profiling method was assessed by sampling and verifying cDNA 
libraries from the three categories see Table 1. Verification was done using EMBL strain 
labels. The cDNA libraries with very low similarities to the B6 strain are from the 
CZECH mouse strain. Based on documented genealogies, the CZECH strain and the B6 
do not seem to share a recent common ancestor (Beck et al., 2000).  Table 1 also shows 
some examples of nonB6 and B6 libraries that were accurately profiled. 
 
Table 1: Verification of the cDNA profiling method 
cDNA library Category Strain-
annotation 
Percentage of identical alleles 
between the B6 and nonB6  strains 
(Standard error of the mean) 
NCI_CGAP_Lu29 nonB6 CZECH II 52.98 (0.311) 
NCI_CGAP_Lu30 nonB6 CZECH II 53.86% (0.40) 
NCI_CGAP_Lu29 lung  tumor nonB6 CZECH II 47.54%  (3.20) 
Mouse Bone Marrow-derived 
Mast Cell Expression Library 
nonB6 BALB/cJ 50% (14.43) 
NIH_BMAP_MAM B6 C57BL/6J 99.90 (0.096) 
Stratagene mouse lung 
937302 

















Figure 5: A flow diagram of the method used to partition cDNA libraries as B6 or nonB6. A) Out of the 667 libraries 
that had ESTs and SNPs mapping to the genome, only 409 cDNA libraries had at least 30 SNPs mapped to them and 
were used for further analysis. 99 clone libraries clearly annotated as C57BL/6J and C57Bl/6J were used to create a 
dataset of SNP alleles highly prevalent in the C57BL/6J strain (ref-B6) B) Percentages of identical alleles were 
computed between each cDNA library and the ref-B6 library. C) A plot of percentage identities and standard error of 
the mean of identical alleles computed in step B. The grey region shows the region with cDNA libraries which could 
not be profiled either as B6 or nonB6 with certainty. D) The final dataset of cDNAs had 382 cDNA libraries classified 











6.3.3 Prevalence of C57BL/6J -specific isoforms 
 
Among the 2149 matrices used for the simulations, we observed 650 matrices that had a 
zero cell (i.e. one combination of strain and mRNA isoform that did not occur) and were 
thus consistent with qualitative allele-specific splicing. In equivalent sets of randomized 
matrices, on average, 497 matrices had a zero element (Figure 6A). The 153 extra 
matrices in the observed data (650 - 497), with at least one zero cell is not likely to have 
resulted from random data with no relationship between strain and transcript isoforms 
and instead indicates the presence of allele-specific isoforms in the data (Figure 5a).  
 
The numbers of matrices (with 95% confidence intervals), with a zero cell from 1000 
simulated replicates are shown in Figure 6A. The horizontal line in Figure 6B shows the 
number of matrices with a zero cell in the observed data. If we consider qualitative allele-
specific splicing as the only alternative to random association (i.e. quantitative allele-
specificity not allowed), the proportion of allele-specific isoforms in the observed data 
can be inferred from the intersection of the horizontal line with the simulated data points. 
This intersection shows additional matrices with a zero cell in the observed data beyond 
what we would expect to occur by chance. We can infer from Figure 6A that the 
proportion of allele-specific splicing most consistent with 150 additional matrices with a 
zero cell in the observed data is 8.4%. The lower (6.6%), and upper bound (10.4%), of 
our estimate were inferred from the span of the confidence interval inferred (Figure 6B). 
 
6.3.4 Gene candidates 
 
A significant proportion of the candidate strain-specific isoforms are likely to be false 
positives due to multiple testing and thus Bonferroni correction for multiple testing was 
performed. However, none of the matrices were statistically significant after the 
correction for multiple testing using the Bonferonni correction and well as less 
conservative methods such as the false discovery approach (Storey and Tibshirani, 2003). 











we present all the top gene candidates, ranked according to the significance of their p-
values (Table 2).  
 
Interestingly, there are also many cases of strain-specific splicing which could be 
functionally important. The strain-specific splicing of a splicing factor (Splicing factor 
3a, subunit 3), could have an impact on the splicing of many other genes. Yet another 
gene candidate which could be an interesting candidate to follow up further is the Breast 
cancer antigen gene (ERGIC3). The strain-specific splicing event we detected is an exon 
8 skipping event. The exon is 32 bps and since it is located in the coding region of the 
gene, it has potential to shift the reading frame. Changes in reading frames can alter 
protein function substantially. Interestingly strain-specific isoforms of this protein have 
also been reported in the SWISSPROT database (Boeckmann et al., 2003). We checked 
for possible splicing mutations in the gene. A SNP (rs27325066) is located 8 bps away 
from the donor site of this exon and could be causing the strain-specific splicing event.   
 
Studies that scan for genes which are differentially expressed in a strain-specific manner 
have also reported numerous gene candidates (Sandberg et al., 2000; Cowles et al., 2002). 
However, most of these studies have not gone as far as elucidating the mechanisms that 
could be causing the differences in expression. In this study we have detected the 
Adenylate cyclase associated protein gene (CAP), highlighted in Table 2, which was 
previously reported to be differentially expressed in a strain-specific manner. Based on 
microarray and semi-quantitative RT-PCR, Sandberg et al., (2000), reported that the CAP 
gene is highly expressed in the in 129SvEv strain in comparison to the C57BL/6J strains. 
The probes used in the microarray experiment could have targeted the strain-specific 
alternatively spliced segment of the CAP mRNA transcript. Hence, the quantitative 
differential expression of the CAP gene in a strain-specific manner reported by Sandberg 















Figure 5: A) A histogram showing the proportion of matrices with a zero cell from 1000 randomized replicates of the 
dataset. The arrow indicates the number of matrices with a zero cell in the observed data B) Average numbers of 
matrices with a zero cell from 1000 simulated replicates of the dataset in which a proportion of the simulated matrices 
are derived from qualitative allele-specific transcript isoforms. The horizontal line shows the number of matrices with a 
zero cell in the observed data. The shaded area shows the confidence interval and the dark line the proportion of 
qualitative allele-specific isoforms most consistent with the observed number of matrices with a zero cell. Error bars 












Table 2: List of top candidates detected using the Fishers’s Exact test
Unigene Cluster` Gene name 
 
Uncorrected p-vaue 
Mm.293096 Hypothetical gene: Unknown function 0.001262626 
Mm.298875 Clathrin, light polypeptide 0.003119719 
Mm.211654 Interferon alpha responsive gene 0.004682274 
Mm.275720 
 
tRNA methyltransferase 1 homolog (S. cerevisiae) 0.004832414 
Mm.298875 Clathrin, light polypeptide 0.005228114 




Mm.276255 Retired 0.008138144 
Mm.25779 Splicing factor 3a, subunit 3 0.009185171 
Mm.141276 Breast cancer  antigen 
 
0.010013526 
Mm.141276 Breast cancer  antigen 
 
0.010013526 
Mm.29424 RIKEN cDNA 2810012G03 
 
0.010989011 
Mm.140761 DnaJ (Hsp40) homolog, subfamily C, member 5 0.011437908 
Mm.9239 Zinc finger protein 
 
0.011904762 
Mm.22519 Ribokinase 0.011904762 
Mm.12967 Inhibitor of kappaB kinase gamma 0.012254902 
Mm.215034 Matrin 3 0.013894152 
Mm.45367 Zinc finger protein 715 0.013986014 





Bromodomain containing 8 0.015870781 
Mm.8687 
 
Adenylate cyclase-associated protein 1 (yeast) 0.016676048 
Mm.276255 Transmembrane protein 134 0.016685206 
Mm.290791 NADH dehydrogenase (ubiquinone) Fe-S protein 1 0.017722011 


























































Insertion of B2 sequence into an 
intron of complement C4 gene in 
H-2k mice resulting in an 
abnormally spliced B2/C4 
transcript plus low expression 














An IAP element in the MIPP gene 
in mouse strains that originated 
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There are over 100 inbred mouse strains with considerable phenotypic and genetic 
diversity that have been deposited into the most comprehensive database dedicated to 
mouse at JAX lab (www.jax.com). The genetic variation between strains, coupled 
with the high isogenicity within strains make mouse ideal as a model for human 
disease and genetic studies (Beck et al., 2000; Wade and Daly, 2005). To further 
enhance the use of mouse for biomedical research, it is imperative to fully understand 
and document the genetic differences and their functional implications that distinguish 
mouse strains (Wade et al., 2005). Such efforts are already underway with the 
establishment of the Mouse Phenome Database in 2001, which catalogues strain-
specific variations including “concealed” phenotypic variation such as gene 
expression (Bogue et al., 2007). However little work has been done to detect or 











large-scale estimation of the prevalence of strain-specific splicing in mouse. Our 
results suggest that approximately 8.4% of mouse alternatively spliced in the ASAPII 
database are spliced differently between B6 and nonB6 strains.  
 
Lack of large-scale comparative studies of strain-specific mRNA splicing is due in 
part to the scarcity of a comprehensive collection of complete mouse strain 
transcriptomes and genomic sequences. However, strain-specific information in 
public repositories of transcript such as EMBL and dbEST has largely been 
disregarded, mainly due to lack or poor annotations of data. We have developed a 
method to categorize transcript data according to mouse inbred strains based on EST-
derived SNPs. This allows for most ESTs to be categorized into their possible strain 
of origin without any strain of origin annotation. 
 
A major advantage of this profiling method is that it provides an indirect means to 
scan for mutations that are likely to cause splicing differences between strains. Unlike 
the marker SNP based studies that are based on ascertaining the presence of a cis-
acting mutation (Nembaware et al., 2004; Ge et al., 2005a), our analysis allows testing 
for strain-specific splicing caused by either cis-acting or trans-acting mutations that 
need not be in linkage disequilibrium with marker SNPs present on the transcript. 
There are many different types of mutations that can affect splicing (Table 3 for 
examples). To have a clear picture of the prevalence of strain specific-splicing one 
should consider all types of mutations that occur in mouse, which include SNPs as 
well as, for example, retrotransposons, that occur at a high frequency in mouse. A 
recent review by Maksakova et al., (2006) highlighted the high rates of endogenous 
retroviral elements in mouse and the impact they can have on the expression of strain-
specific transcripts.  
 
When designing a study of strain-specific splicing or gene expression, it is 
informative to trace the origins of the mutations along the mouse genealogical trees. 
Splicing mutations acquired and fixed during the propagation of a mouse inbred 
founder are likely to be detectable in strains that form the genealogical branches 
thereafter. For example, the presence of a single long terminal repeat (LTR), in the 
mouse intracisternal A particle (IAP) promoted placental gene (IPP), results in the 











C3H/HeJ and BALB/c (Chang-Yeh et al., 1993) that share a common ancestry of the 
Bagg’s Albino mouse ancestor (Beck et al., 2000). An IAP retrotransposition event 
that could have occurred in a germline cell of a Bagg’ s Albino mice followed by 
subsequent removal of the IAP is suggested to have left the LTR remnant sequence 
that causes the observed strain-specific splicing event (Chang-Yeh et al., 1993). Using 
the SNP profiling method allows us to check for strain-specific mutations that 
occurred along the genealogies of the C57BL/6J and its related mouse strains.  
 
EST sequences provide transcript information for different mouse strains, but ESTs 
are sparse for most gene segments except for the 3’ and 5’ gene ends. For the 
simulations there is enough data in the matrices to make an estimate of the prevalence 
of B6 strain-specific splicing (Figure 4). However, for the detection of individual gene 
candidates, there is insufficient data. The SCNM1 gene example in Figure 4 
demonstrates that the EST data is too sparse to confirm most published cases of 
strain-specific splicing. An alternative approach would be to perform an analogous 
study to that performed on the Affymetrix exon array platforms (Chapter 5). 
However, thus far, high quality exon array data is mainly based on single mouse 
strains and thus not ideal to study strain-specific splicing (Pan et al., 2004). 
Furthermore, the equivalent of the human lymphoblastoid cell lines genotyped 
through the HapMap project (The International HapMap Consortium, 2005) and 
subsequently profiled using affymetrix exon arrays (Huang et al., 2007) is not 
available for mouse. 
 
Differences in gene expression between mouse strains are frequently investigated with 
quantitative considerations of transcriptional efficiency in mind (Cowles et al., 2002; 
Sandberg et al., 2000)  A significant number of studies have measured gene 
expression variation across strains using microarray platforms. However, array studies 
are based on probes which are normally randomly primed from EST data (Sandberg et 
al., 2000). A limitation of EST based probes is that they could be targeting strain-
specific splicing events which can potentially be detected on array platforms as 
differential expression in mouse strains. In this current study, we detected one such 
gene. In light of this result, we propose that studies of strain-specific expression 
should consider whether there is evidence of strain-specific splicing in the genes 












A genome-wide study of the prevalence of strain-specific isoforms serves to 
emphasize to mouse researchers, the importance of detection of all possible mRNA 
isoforms before the designing a mouse knock-out experiment. Inaccurate prediction of 
alternatively spliced transcripts could lead to poor experimental design primarily 
during creation of gene knockout strains. A classic example is a mouse strain 
designed as a gene knockout strain of an estrogen alpha receptor that had a placental 
specific mRNA isoform which escaped the knockout (Kol et al., 2005). In the 
eostrogen alpha receptor gene knockout experiment described above, lack of 
knowledge of alternative isoforms led to years of work with questionable conclusions 
which could have been avoided had the researchers been aware of all the transcript 
isoforms. A similar error occurred in the creation of a knockout strain of the Vitamin 
D Receptor (VDR) gene, a truncated form of the supposedly knocked-out VDR gene 
was discovered recently (Bula et al., 2005). 
 
We have used transcript data to partition transcript as having originated from B6-like 
strains and nonB6 strains. From our estimates we conclude that there is a high 
prevalence of B6 specific splicing which suggests a high prevalence of strain-specific 
splicing in general. A recent study, has led to an influx of over 8 million mouse SNPs 
in dbSNP (Frazer et al., 2007), which greatly increased the number of mouse SNPs in 
dbSNPs. With such large amounts of sequence variants, a scan for strain-specific 
splicing using SNP data and splicing scoring tools such as was performed in Chapter 
5, could add value to this area of research. However, this study has provided a basis 






















Conclusion and Future work 
 
_____________________________________________________________________ 
Completion of the human genome project and improvements in large-scale 
transcriptome and genotyping capturing technologies has lead to large amounts of 
data being deposited into publicly available databases. Publicly available 
transcriptome data and sequence variants are generated from individuals of diverse 
genetic backgrounds, and hence offer great opportunities to understand the impact of 
heritable sequence variants on gene expression variability. How best to make use of 
the publicly available datasets in deducing the effect of a cis- cting mutation on the 
regulation of any of the mechanisms involved in gene expression, remains an open 
question.  
 
Several studies have developed algorithms that make use of publicly available 
genome-wide transcript and sequence data and have generally concluded that cis-
acting variants contribute significantly to allele-specific expression (see Chapter 1 and 
Chapter 2). However the influence of genotypes on mRNA splicing patterns is a 
largely unexplored area of research. Work from this thesis has contributed towards 
understanding the contribution of heritable genetic variations to mRNA transcript 
diversity through the detection and characterization of allele-specific splicing using 
publicly available datasets. Simultaneously, work from this thesis has made a 
significant contribution to the general characterisation of isoforms generated from 
alternative and allele-specific mRNA splicing (Figure 1). In this chapter, significant 














Figure 1: Major contributions in genome-wide detection and estimation of alternatively spliced mRNA isoforms 
in human. Published contributions from this thesis are highlighted in green.  
 
7.1 High prevalence of allele-specific splicing 
 
Although many attempts have been made to assess the prevalence of allele-specific 
splicing in human, they are generally biased towards splice variants that cause disease 
(Lopez-Bigas et al., 2005) or mutations at splice donor and acceptor sites (Krawczak 
et al., 1992). Work from this thesis was the first to report a genome-wide detection of 
allele-specific splicing that is not restricted to any disease or to a specific cis-
regulatory element (Figure 1). Our results in Chapter 4 and 6 indicate a high 
prevalence of allele-specific splicing in human and mouse and these initial findings  
were corroborated by the large numbers of individual genes affected by allele-specific 
splicing reported in Chapter 5. 
 
Such a high prevalence suggests that allele-specific splicing could be a common 
source of inter-individual transcript variability which ultimately leads to phenotypic 
differences. Although the functional roles of the allele-specific isoforms may not be 
obvious from computational analyses alone, we have highlighted the potential impact 
that allele-specific splicing can have on disease (Chapter 2 and 5). The reported allele-
specific splicing candidates are likely to have a large impact on disease and 











7.2 Improvement in the detection of splicing mutations  
 
Splicing mutations when located in coding regions are commonly misclassified as 
causing phenotypic variations through non-synonymous amino acid changes (Cartegni 
et al., 2003). The GLO1 gene discussed in Chapter 5 highlights how such 
misclassifications are bound to occur. At present, no single source of publicly 
available datasets can provide information about splicing is-acting mutations and all 
the resultant allele-specific splicing products. Each source of data has its own 
advantages as well as disadvantages (Chapter 5). The integrated approach of using 
three different publicly available datasets (ESTs, microarrays and genomic 
sequences), produces both putative splicing mutations and their allele-specific 
splicing products. Therefore we recommend such integrated approaches for more 
accurate inferences of the impact of mutations on mRNA splicing patterns. 
 
The availability of putative cis-acting mutations and their resultant allele-specific 
mRNA isoforms allows for a less time consuming way for designing minigene assays 
or any other experiments to validate allele-specific splicing patterns. Therefore, work 
from this thesis has contributed to the improvement of the detection of splicing 
mutations by providing an extensive resource that can be used to assess the possible 
effect on splicing of human polymorphisms located in putative splice-regulatory sites. 
This allows researchers to make more informed decision when pursuing functional 
characterisation of mutations that are already associated to disease.  
 
7.3 Novel methods for using publicly available ESTs in allele-
specific splicing 
 
Two types of data from large-scale analyses are commonly used; genomic and 
microarrays and thus computational tools for analysing allele-specific splicing in 
microarray and genomic datasets are well established. This contrasts sharply with 
methods for detection of allele-specific splicing based on ESTs since these transcripts 
have generally been underutilised. A major contribution of this work is the 
development of two useful methods, a heuristic and maximum likelihood approach 












7.4 Summary of resources 
 
We provide several resources (see Table 1) that can be used to accelerate the 
investigation of allele-specific splicing as well as other allele-specific gene expression 
variation.  For example the snp2estMap that is presented in Chapter 3 has already 
been used for studying allele-specific imprinting (Seoighe et al., 2006).  
 
Table 1: Summary of data contributions 
Chapter Resource Input data Location 
3 snp2estmap ESTs http://mancala.cbio.uct.ac.za/splici
ng 








7.5 Future work 
7.5.1 Expansion of the snp2estmap database 
 
The snp2estmap database presented in Chapter 3 only contains human data. 
Expansion of this resource to include SNPs mapped to ESTs of all the highly 
represented multi-exon organisms in dbEST would greatly accelerate the use of ESTs 
in the detection of allele-specific splicing across phyla. 
 
7.5.2 Maximum Likelihood Models  
 
The significance of the statistical models developed in a maximum likelihood 
framework extends beyond the detection of allele-specific splicing, to the detection of 
allele-specific expression (Seoighe et al., 2006). The maximum likelihood models 
could also easily be adjusted to detect allele-specific splicing that occurs in a context 
specific manner such as in a tissue-specific (Cowles et al., 2002) or disease specific 
manner (Wang and Cooper, 2007). Work is already underway to analyze allele-
specific splicing that occurs in a cancer-specific manner, based on the snp2estmap 












The detection of allele-specific splicing in Chapter 4, 5 and 6 is based on the 
assumption that SNP markers used for the detection of allele-specific splicing are in 
linkage disequilibrium with cis-acting splicing mutations. However, this assumption 
was not been tested. Based on haplotype blocks that have already been characterized 
by the HapMap project (The International HapMap Consortium, 2005), statistical 
models could be developed that estimate the likelihood of marker SNPs being in 
linkage disequilibrium with putative cis-splicing mutations. For future work, such an 
approach, if applied to results from this study would greatly substantiate and add 




7.5.2 Further functional characterization of allele-specific isoforms  
 
An exciting and promising direction for further research is characterization of the 
direct impact of allele-specific splicing patterns identified from this study on human 
phenotypic variation. Putative cis-acting variants discovered in this study that have 
already been associated to disease, cancers and pharmacogenetics in publicly 
available database such as the PharmGKB database (Altman, 2007) and the Human 
Gene Mutation Disease Database (Stenson et al., 2003) would be an ideal starting 
point. Knowledge of allele-specific splicing patterns caused by mutations already 
associated to disease could significantly enhance the design and development of more 
effective therapies. 
There are several reports of splicing factors that are modifiers to disease. Some of the 
allele-specific splicing candidates discovered (see Chapter 5) are involved in the 
regulation of splicing. Future work that focuses of characterising allele-specific 
splicing of splicing regulators could be of great medical significance.  
Although the computational and microarray approaches presented in this thesis are 
invaluable for identifying putative srSNPs of medical significance, they are associated 
with several shortcomings. Work is currently underway by a collaborating group to 
validate some of the novel candidates presented in this study through the use of RT-












7.6 Concluding remarks  
 
The medical impact of allele-specific splicing is apparent from the ever-increasing 
number of genetic diseases and pharmacogenetic effects that are linked to splicing 
defects (Faustino and Cooper, 2003; Wang and Cooper, 2007). A thorough 
description and cataloguing of all human genotypes and the quantitative and 
qualitative effect they exert on splicing would be a powerful resource for 
understanding human genetic diseases and phenotypes. The role of computational 
based analysis of publicly available genome-wide datasets promises to be increasingly 
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